var title_f27_53_28496="Methylene blue stool";
var content_f27_53_28496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Methylene blue stool",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28496=[""].join("\n");
var outline_f27_53_28496=null;
var title_f27_53_28497="Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for ST elevation acute myocardial infarction";
var content_f27_53_28497=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"TIMI_STEMI_form\" name=\"TIMI_STEMI_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for ST elevation acute myocardial infarction",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"TIMI_STEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           DM, history of HTN or history of Angina (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"TIMI_STEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Systolic blood pressure less than 100 mm Hg (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"TIMI_STEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Heart rate greater than 100 BPM (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"TIMI_STEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Killip class II-IV (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"TIMI_STEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Body weight less than 150 lb or 67 kg (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"TIMI_STEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Anterior lead ST elevation or left BBB (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"TIMI_STEMI_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Time to treat more than 4 hours (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Age",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"TIMI_STEMI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;=75 years old (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"TIMI_STEMI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           65-74 years old (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"TIMI_STEMI_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Less than 65 (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          TIMI Risk Score Predicts 30 Day Mortality After an MI",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           0.8%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           1 Point:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           1.6%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           2 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           2.2%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_4\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           3 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           4.4%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_5\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           4 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           7.3%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_6\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           5 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           12%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_7\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           6 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           16%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_8\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           7 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           23%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_9\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           8 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           27%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_10\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           9-14 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           36%",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"      Entry criteria: Chest pain for more than 30 minutes, ST elevation, symptom onset less than 6 hours, fibrinolytic eligible",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Morrow DA, Antman EM, Charlesworth A, et. al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy.",
"        <i>",
"         Circulation",
"        </i>",
"        . 2000 Oct 24;102(17):2031-7.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"TIMI_STEMI_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28497=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function TIMI_STEMI_fx() {",
"with(document.TIMI_STEMI_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1.checked){",
"Score = Score + 1;",
"}",
"if (cc2.checked){",
"Score = Score + 3;",
"}",
"if (cc3.checked){",
"Score = Score + 2;",
"}",
"if (cc4.checked){",
"Score = Score + 2;",
"}",
"if (cc5.checked){",
"Score = Score + 1;",
"}",
"if (cc6.checked){",
"Score = Score + 1;",
"}",
"if (cc7.checked){",
"Score = Score + 1;",
"}",
"if (cc8[0].checked){",
"Score = Score + 3;",
"}",
"if (cc8[1].checked){",
"Score = Score + 2;",
"}",
"if (cc8[2].checked){",
"Score = Score + 0;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 0) && (Score <= 0)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 1) && (Score <= 1)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Score >= 2) && (Score <= 2)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if ((Score >= 3) && (Score <= 3)){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"if ((Score >= 4) && (Score <= 4)){ document.getElementById('rr1_5').bgColor = '#cccccc';",
"}",
"if ((Score >= 5) && (Score <= 5)){ document.getElementById('rr1_6').bgColor = '#cccccc';",
"}",
"if ((Score >= 6) && (Score <= 6)){ document.getElementById('rr1_7').bgColor = '#cccccc';",
"}",
"if ((Score >= 7) && (Score <= 7)){ document.getElementById('rr1_8').bgColor = '#cccccc';",
"}",
"if ((Score >= 8) && (Score <= 8)){ document.getElementById('rr1_9').bgColor = '#cccccc';",
"}",
"if ((Score >= 9) && (Score <= 14)){ document.getElementById('rr1_10').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"document.getElementById('rr1_5').bgColor = \"\";",
"document.getElementById('rr1_6').bgColor = \"\";",
"document.getElementById('rr1_7').bgColor = \"\";",
"document.getElementById('rr1_8').bgColor = \"\";",
"document.getElementById('rr1_9').bgColor = \"\";",
"document.getElementById('rr1_10').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f27_53_28497=null;
var title_f27_53_28498="Patient information: Preeclampsia (The Basics)";
var content_f27_53_28498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/21/16723\">",
"         Patient information: C-section (cesarean delivery) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/46/29410\">",
"         Patient information: HELLP syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/32/7682\">",
"         Patient information: High blood pressure and pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/42/21155\">",
"         Patient information: Swelling (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/53/32594\">",
"         Patient information: Edema (swelling) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/54/33635\">",
"         Patient information: High blood pressure in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/32/37380\">",
"         Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/58/40867\">",
"         Patient information: Preeclampsia (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Preeclampsia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/preeclampsia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H30482008\">",
"      <span class=\"h1\">",
"       What is preeclampsia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Preeclampsia is a dangerous condition that some women get when they are pregnant. It usually happens during the second half of pregnancy (after 20 weeks). It can also happen during labor or after the baby is born.",
"     </p>",
"     <p>",
"      Women with preeclampsia have high blood pressure and too much protein in their urine. They can also have other serious problems, such as with their liver or kidney. Plus, the baby may not grow well and be small.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30482015\">",
"      <span class=\"h1\">",
"       What are the symptoms of preeclampsia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most women with preeclampsia do not feel any different than usual. Preeclampsia usually does not cause symptoms unless it is severe. Signs and symptoms of severe preeclampsia are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A bad headache",
"       </li>",
"       <li>",
"        Changes in vision: blurry vision, flashes of light, spots",
"       </li>",
"       <li>",
"        Urinating less often than usual",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Belly pain, especially in the upper belly",
"       </li>",
"       <li>",
"        Swelling of the face and hands",
"       </li>",
"       <li>",
"        Sudden weight gain (more than 2 pounds in a week)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have any of these symptoms, tell your doctor or nurse. You may not have preeclampsia, because these symptoms can also occur in normal pregnancies. But it&rsquo;s important that your doctor know about them.",
"     </p>",
"     <p>",
"      You should also call your doctor or nurse if you have bleeding from the vagina.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30482022\">",
"      <span class=\"h1\">",
"       How might preeclampsia affect my baby?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Preeclampsia can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Slow the growth of the baby",
"       </li>",
"       <li>",
"        Decrease the amount of amniotic fluid around the baby (amniotic fluid is the liquid that surrounds and protects the baby in the uterus)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should call your doctor or nurse if your baby is not moving as much as usual. Your doctor or nurse will do tests to check for any problems with the baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30482029\">",
"      <span class=\"h1\">",
"       Is there a test for preeclampsia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To test for preeclampsia, your doctor or nurse will take your blood pressure and check your urine for protein at each visit during pregnancy.",
"     </p>",
"     <p>",
"      When your doctor or nurse tells you your blood pressure, he or she will say two numbers. For instance, your doctor or nurse might say that your blood pressure is &ldquo;140 over 90.&rdquo; To be diagnosed with preeclampsia, your top number (called &ldquo;systolic pressure&rdquo;) must be 140 or higher, or your bottom number (called &ldquo;diastolic pressure&rdquo;) must be 90 or higher. Plus, you must have too much protein in your urine.",
"     </p>",
"     <p>",
"      It is possible to have high blood pressure (above",
"      <span class=\"nowrap\">",
"       140/90)",
"      </span>",
"      during pregnancy without having high protein in the urine. That is not preeclampsia. Still, if you develop high blood pressure, your doctor will watch you closely. You could develop preeclampsia or other problems related to high blood pressure.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30482036\">",
"      <span class=\"h1\">",
"       How is preeclampsia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The only cure for preeclampsia is to deliver the baby. Your doctor or nurse will decide whether it is better for you to have your baby right away, or to wait.",
"     </p>",
"     <p>",
"      If you are near your due date, your doctor will probably give you medicine to start contractions. This is called &ldquo;inducing labor.&rdquo; Most women are able to give birth the usual way, through the vagina. But in some cases the doctor will need to do a C-section. A C-section, or &ldquo;cesarean delivery,&rdquo; is a type of surgery used to get the baby out of the uterus.",
"     </p>",
"     <p>",
"      If your due date is not for several weeks, and your preeclampsia is not severe, your doctor or nurse might wait to deliver your baby. This is to give the baby more time to grow and develop. If your doctor or nurse decides to wait, he or she will check you and your baby often for any problems. You may need to stay in the hospital.",
"     </p>",
"     <p>",
"      If your blood pressure is very high, your doctor or nurse might give you medicine to lower blood pressure. This is to keep you from having a stroke.",
"     </p>",
"     <p>",
"      Women with preeclampsia can sometimes have seizures. Your doctor or nurse will probably give you medicine during labor to prevent this.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30482043\">",
"      <span class=\"h1\">",
"       What can I do to prevent preeclampsia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can&rsquo;t do anything to keep from getting preeclampsia. The most important thing you can do is to keep all the appointments you have with your doctor, nurse, or midwife. That way, they can find out as soon as possible if your blood pressure goes up or if you have too much protein in your urine. Also, call them right away if you have symptoms of preeclampsia or the baby isn&rsquo;t moving as much as usual. Your doctor or nurse can do things to keep you from having worse problems from preeclampsia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30482050\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=see_link\">",
"       Patient information: Swelling (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=see_link\">",
"       Patient information: High blood pressure and pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/46/29410?source=see_link\">",
"       Patient information: HELLP syndrome (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=see_link\">",
"       Patient information: Preeclampsia (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"       Patient information: High blood pressure in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"       Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=see_link\">",
"       Patient information: Edema (swelling) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/53/28498?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15598 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28498=[""].join("\n");
var outline_f27_53_28498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482008\">",
"      What is preeclampsia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482015\">",
"      What are the symptoms of preeclampsia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482022\">",
"      How might preeclampsia affect my baby?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482029\">",
"      Is there a test for preeclampsia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482036\">",
"      How is preeclampsia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482043\">",
"      What can I do to prevent preeclampsia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30482050\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=related_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/46/29410?source=related_link\">",
"      Patient information: HELLP syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=related_link\">",
"      Patient information: High blood pressure and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=related_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=related_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_53_28499="Kidney stones in adults";
var content_f27_53_28499=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Kidney stones in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/53/28499/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28499/contributors\" id=\"au4097\">",
"       Glenn M Preminger, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28499/contributors\" id=\"au6134\">",
"       Gary C Curhan, MD, ScD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/53/28499/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28499/contributors\" id=\"se69\">",
"       Stanley Goldfarb, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28499/contributors\" id=\"se158\">",
"       Michael P O'Leary, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/53/28499/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28499/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?27/53/28499?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      KIDNEY STONES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Kidney stones (also called nephrolithiasis or urolithiasis) affect approximately 1 in 11 people (19 percent of men and 9 percent of women by age 70 years). Fortunately, treatment is available to effectively manage most stones. In addition, you can take steps to prevent kidney stones from recurring.",
"    </p>",
"    <p>",
"     A detailed review of kidney stones in children is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/26/15779?source=see_link\">",
"      \"Patient information: Kidney stones in children (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information about kidney stones is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link\">",
"      \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HOW KIDNEY STONES DEVELOP",
"     </span>",
"    </p>",
"    <p>",
"     A kidney stone can form when substances such as calcium, oxalate, cystine, or uric acid are at high levels in the urine. Stones can also form if these substances are at normal levels, especially if the amount of urine made each day is low. The substances form crystals, which become anchored in the kidney and gradually increase in size, forming a kidney stone.",
"    </p>",
"    <p>",
"     Typically, the stone will move through the urinary tract (",
"     <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"      figure 1",
"     </a>",
"     ) and is passed out of the body in the urine. A stone may cause pain if it becomes stuck and blocks the flow of urine. Large stones do not always pass on their own and sometimes require a minimally invasive surgical procedure to remove them.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      KIDNEY STONE RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Certain diseases, dietary habits, or medications can increase your risk of developing kidney stones (",
"     <a class=\"graphic graphic_table graphicRef64849 \" href=\"UTD.htm?16/43/17083\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      KIDNEY STONE SYMPTOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pain is the most common symptom of kidney stones. Pain can range from a mild and barely noticeable ache to discomfort that is so intense it requires treatment in the hospital. Typically, the pain gets worse and better, but does not go away completely. Waves of severe pain, known as renal colic, usually last 20 to 60 minutes. Pain can occur in the flank (the side, between the ribs and the hip) or the lower abdomen (",
"     <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Blood in the urine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with kidney stones will have blood in the urine (hematuria). The urine may be pink or reddish, or the blood may be visible only with urine dipstick testing or microscopic examination of the urine. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=see_link\">",
"      \"Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Gravel",
"     </span>",
"     &nbsp;&mdash;&nbsp;You may pass \"gravel\" or small stones in your urine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Other symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other kidney stone symptoms include nausea or vomiting, pain with urination, and an urgent need to urinate.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Asymptomatic kidney stones",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people with kidney stones have no symptoms (asymptomatic means without symptoms). These kidney stones are usually found when an imaging study (such as an ultrasound, x-ray or CT scan) is performed for other purposes. Stones can remain in the kidneys for many years without ever causing symptoms. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39847?source=see_link\">",
"      \"The first kidney stone and asymptomatic nephrolithiasis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      KIDNEY STONE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Kidney stones are usually diagnosed based upon your symptoms, a physical examination, and imaging studies.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Computed tomography (CT) scan",
"     </span>",
"     &nbsp;&mdash;&nbsp;A CT scan creates a three dimensional image of structures within the body. A particular type of CT scan (called noncontrast helical CT) is often recommended if kidney stones are suspected.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;An ultrasound (or sonogram) can also be used to detect kidney stones, although small stones or stones in the ureters (kidney tubes) may be missed. However, ultrasound is the procedure of choice for people who should avoid radiation, including pregnant women and children.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      KIDNEY STONE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of kidney stones depends upon the size and location of your stone, as well as your pain and ability to keep down fluids. If your stone is likely to pass, your pain is tolerable, you are able to eat and drink, and you can be treated at home.",
"    </p>",
"    <p>",
"     If you have severe pain or nausea, you will need to be treated with stronger pain medications and IV fluids, which are often given in the hospital. In addition, patients with stones and who also have a fever should be treated in the hospital as soon as possible to avoid a life-threatening infection. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=see_link\">",
"      \"Options in the management of renal and ureteral stones in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Home treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;You can take non-prescription pain medication until the stone passes. This includes nonsteroidal antiinflammatory drugs such as ibuprofen (Advil, Motrin) or naproxen (Aleve).",
"    </p>",
"    <p>",
"     Other medications, such as tamsulosin (Flomax&reg;), may also be recommended to speed the passage of stones.",
"    </p>",
"    <p>",
"     You will probably be asked to strain your urine to recover the stone; it can then be analyzed in a laboratory to determine the content of the stone (eg, calcium, uric acid, etc). Knowing what type of kidney stone you have is important in planning treatments to prevent future stones (see",
"     <a class=\"local\" href=\"#H20\">",
"      'Kidney stone prevention'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      If the stone does not pass",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stones larger than 9 or 10 millimeters rarely pass on their own and generally require a procedure to break up or remove the stone. Some smaller stones also do not pass. Several procedures are available.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Shock wave lithotripsy (SWL)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lithotripsy is the treatment of choice in many patients who need help passing a stone. Lithotripsy is particularly good for stones 1 cm or less in the kidney and upper ureter. Lithotripsy is not effective for treating large or hard stones. You may require medication to make you sleepy and reduce pain during lithotripsy treatment, although this depends upon the type of lithotripsy equipment used.",
"    </p>",
"    <p>",
"     Lithotripsy is done by directing high-energy shock waves toward the stone. These sound waves pass through the skin and bodily tissues and release energy at the stone surface. This energy causes the stone to break into fragments that can be more easily passed in the urine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Percutaneous nephrolithotomy (PNL)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Extremely large or complex stones, or stones resistant to shock wave lithotripsy, may require a minimally invasive surgical procedure to remove the stone. In this procedure, small endoscopic (telescopic) instruments are passed through the skin (percutaneously) into the kidney to remove the stone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Ureteroscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ureteroscopy is another type of endoscopic procedure that uses a thin scope, which is passed through the urethra and bladder, into the ureter and kidney. This endoscope allows the urologist to see the stone and remove it, or to break it up into smaller pieces that can pass more easily. Ureteroscopy is often used to remove stones blocking the ureter, and sometimes for small stones in the kidney.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Treatment of asymptomatic stones",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have a kidney stone that is causing no symptoms, you may or may not need to remove the stone. The decision is based upon the size and location of your stone, as well as your ability to be treated quickly if symptoms were to develop. If there is a chance that you would not be able to get treatment quickly (eg, if you travel frequently), you are more likely to need to have the stone removed.",
"    </p>",
"    <p>",
"     Regardless of the decision to treat or not, you should be evaluated for underlying health conditions that can increase the risk of kidney stones (",
"     <a class=\"graphic graphic_table graphicRef64849 \" href=\"UTD.htm?16/43/17083\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      KIDNEY STONE PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     After you have a kidney stone, you should have blood and urine tests to determine if you have certain health problems or dietary issues that increase the risk of kidney stones (",
"     <a class=\"graphic graphic_table graphicRef64849 \" href=\"UTD.htm?16/43/17083\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     If you passed and saved the stone, it should be analyzed to determine the type of stone. In addition, your clinician may request that you perform a 24-hour urine collection (all the urine you make over a 24-hour period) to determine underlying risk factors for your kidney stone disease. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"      \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Based upon these test results, one or more of the following may be recommended:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       You may be given a medication to reduce the risk of future stones.",
"      </li>",
"      <li>",
"       You may be advised to drink more fluids to decrease the risk of another stone. The goal is to increase the amount of urine that flows through your kidneys and also to lower the concentrations of substances that promote stone formation. Experts recommend drinking enough fluid that you make more than 2 liters of urine per day.",
"      </li>",
"      <li>",
"       You may be advised to make changes in your diet; the changes recommended will depend upon the type of kidney stone you have.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A kidney stone can form when there are normal or high levels of certain substances in the urine. These substances can form crystals. Crystals become attached to the kidney and gradually increase in size, forming a stone.",
"      </li>",
"      <li>",
"       Eventually, the stone moves through the urinary tract and is passed in the urine. Or, the stone can remain in the urinary tract, blocking urine flow, which can cause pain.",
"      </li>",
"      <li>",
"       Certain diseases and habits can affect a person's risk for developing kidney stones. These include a past history or family history of kidney stones, certain dietary habits, underlying medical problems, certain medications, and dehydration (",
"       <a class=\"graphic graphic_table graphicRef64849 \" href=\"UTD.htm?16/43/17083\">",
"        table 1",
"       </a>",
"       )&nbsp;(see",
"       <a class=\"local\" href=\"#H3\">",
"        'Kidney stone risk factors'",
"       </a>",
"       above).",
"      </li>",
"      <li>",
"       The most common symptom of a kidney stone is pain; other symptoms include hematuria (blood in the urine), passing gravel, nausea, vomiting, pain with urination, and an urgent need to urinate. Many patients with kidney stones have no symptoms (see",
"       <a class=\"local\" href=\"#H4\">",
"        'Kidney stone symptoms'",
"       </a>",
"       above).",
"      </li>",
"      <li>",
"       Testing is usually needed to diagnose a kidney stone. Computed tomography (CT scan) is the preferred test for most patients (see",
"       <a class=\"local\" href=\"#H10\">",
"        'Kidney stone diagnosis'",
"       </a>",
"       above).",
"      </li>",
"      <li>",
"       Treatment usually includes pain medication and increased fluids (to drink) until the stone is passed. Over the counter pain medication (eg, ibuprofen) may be helpful. If the pain is not controlled, a stronger medication (narcotic) may be needed. In addition, certain medications may be prescribed to increase the likelihood of stone passage (ie, tamsulosin) (see",
"       <a class=\"local\" href=\"#H14\">",
"        'Home treatment'",
"       </a>",
"       above).",
"      </li>",
"      <li>",
"       Small stones (less than 5 millimeters) usually pass without treatment. Larger stones (9 millimeters or greater) rarely pass on their own. Treatment for larger stones is usually done in a hospital (see",
"       <a class=\"local\" href=\"#H15\">",
"        'If the stone does not pass'",
"       </a>",
"       above).",
"      </li>",
"      <li>",
"       Further testing is recommended for patients with recurrent kidney stones or in first-time stone formers who may be at risk for additional stone formation. Tests help to determine if an illness is causing kidney stones to form. Medications may be prescribed to prevent future stones. Drinking more fluids and changing the diet can help to prevent future kidney stones (",
"       <a class=\"graphic graphic_table graphicRef64849 \" href=\"UTD.htm?16/43/17083\">",
"        table 1",
"       </a>",
"       )&nbsp;(see",
"       <a class=\"local\" href=\"#H20\">",
"        'Kidney stone prevention'",
"       </a>",
"       above).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498680746\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6599966\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/56/43905?source=see_link\">",
"      Patient information: Kidney stones in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/38/27234?source=see_link\">",
"      Patient information: Kidney stones in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/44/35523?source=see_link\">",
"      Patient information: Polycystic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/48/8962?source=see_link\">",
"      Patient information: Acute abdomen (belly pain) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/5/37970?source=see_link\">",
"      Patient information: Hydronephrosis in adults (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6600020\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/26/15779?source=see_link\">",
"      Patient information: Kidney stones in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=see_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30756?source=see_link\">",
"      Clinical significance of residual stone fragments following stone removal",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=see_link\">",
"      Cystine stones",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=see_link\">",
"      Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40231?source=see_link\">",
"      Management of struvite or staghorn calculi",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27079?source=see_link\">",
"      Management of ureteral calculi",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38340?source=see_link\">",
"      Nephrolithiasis during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=see_link\">",
"      Nephrolithiasis in renal tubular acidosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=see_link\">",
"      Options in the management of renal and ureteral stones in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=see_link\">",
"      Pathogenesis and clinical manifestations of struvite stones",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/10/27812?source=see_link\">",
"      Renal complications of extracorporeal shock wave lithotripsy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39847?source=see_link\">",
"      The first kidney stone and asymptomatic nephrolithiasis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/\">",
"      www.kidney.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?27/53/28499/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?27/53/28499?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28499/abstract/1\">",
"      Glowacki LS, Beecroft ML, Cook RJ, et al. The natural history of asymptomatic urolithiasis. J Urol 1992; 147:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28499/abstract/2\">",
"      Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28499/abstract/3\">",
"      Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002; 346:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28499/abstract/4\">",
"      Preminger GM, Tiselius HG, Assimos DG, et al. 2007 guideline for the management of ureteral calculi. J Urol 2007; 178:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28499/abstract/5\">",
"      Hollingsworth JM, Rogers MA, Kaufman SR, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 2006; 368:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28499/abstract/6\">",
"      Auge BK, Preminger GM. Update on shock wave lithotripsy technology. Curr Opin Urol 2002; 12:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28499/abstract/7\">",
"      Auge BK, Preminger GM. Surgical management of urolithiasis. Endocrinol Metab Clin North Am 2002; 31:1065.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f27_53_28499=[""].join("\n");
var outline_f27_53_28499=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           KIDNEY STONES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HOW KIDNEY STONES DEVELOP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           KIDNEY STONE RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           KIDNEY STONE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           KIDNEY STONE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           KIDNEY STONE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           KIDNEY STONE PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\" title=\"figure 1\">",
"           Urinary tract anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?16/43/17083\" title=\"table 1\">",
"           Risks kidney stones PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f27_53_28500="Normal bone marrow Low";
var content_f27_53_28500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal bone marrow biopsy at low power",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a normal bone marrow biopsy. The overall cellularity is between 30 and 70 percent, with the remainder of the space being occupied by fat and stroma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28500=[""].join("\n");
var outline_f27_53_28500=null;
var title_f27_53_28501="Fesoterodine: Drug information";
var content_f27_53_28501=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fesoterodine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/34/12836?source=see_link\">",
"    see \"Fesoterodine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6788469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Toviaz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6821328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6821362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Overactive bladder:",
"     </b>",
"     Oral: 4 mg once daily; may be increased to 8 mg once daily based on individual response and tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosing adjustment for concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin):",
"     </i>",
"     4 mg once daily; maximum dose: 4 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6821363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6821359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 4 mg once daily; maximum dose: 4 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6821360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe impairment (Child-Pugh class C): Use is not recommended; has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6821368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as fumarate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toviaz&reg;: 4 mg, 8 mg [contains soya lecithin]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6821326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6821366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food. Swallow whole; do not chew, crush, or divide.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6821330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6821325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fesoterodine may be confused with fexofenadine, tolterodine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6821340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Gastrointestinal: Xerostomia (19% to 35%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatological: Rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (4% to 6%), dyspepsia (2%), nausea (1% to 2%), abdominal pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (3% to 4%), dysuria (1% to 2%), urinary retention (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (1%), GGT increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Dry eyes (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (2% to 3%), cough (1% to 2%), dry throat (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Peripheral edema (1%)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     &lt;1% (Limited to important or life-threatening): Angina, angioedema, diverticulitis, gastroenteritis, heat prostration, hypersensitivity reactions, irritable bowel syndrome, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6821335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fesoterodine or tolterodine (both are metabolized to 5-hydroxymethyl tolterodine) or any component of the formulation; urinary retention; gastric retention; uncontrolled narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6821336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angioedema: Cases of angioedema involving the face, lips, tongue, and/or larynx have been reported. Discontinue immediately if tongue, hypopharynx, or larynx are involved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS effects: Anticholinergics may cause drowsiness, dizziness, headache, and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Dose reduction or discontinuation should be considered if CNS effects occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heat prostration: May occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bladder flow obstruction: Use with caution in patients with bladder flow obstruction; may increase the risk of urinary retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal obstructive disorders: Use with caution in patients with decreased GI motility or gastrointestinal obstructive disorders (ie, pyloric stenosis); may increase the risk of gastric retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Glaucoma: Use with caution in patients with controlled (treated) narrow-angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: No dosing adjustments recommended for patients with mild-or-moderate hepatic impairment. No studies have been performed in patients with severe hepatic impairment (Child-Pugh class C); use is not recommended in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dose adjustment recommended in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute). There are no dosing adjustments for patients with mild-to-moderate renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Doses &gt;4 mg are not recommended in patients receiving strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin). No dosing adjustments are recommended in patients receiving moderate CYP3A4 inhibitors (eg, erythromycin, fluconazole, diltiazem, verapamil, grapefruit juice).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Medication associated with potent anticholinergic properties which may be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) (Beers Criteria). In addition, risk of adverse effects may be increased in elderly patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6833846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors: May increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Fesoterodine. Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6821344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Ethanol may potentiate adverse effects. Management: Avoid alcohol.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6821331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6821332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6821334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16355062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if fesoterodine is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6821365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Toviaz Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $189.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (30): $189.73",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Toviaz (BE, CH, CZ, DE, DK, EE, GB, GR, HK, ID, IE, IL, IT, KP, MY, NL, NO, PH, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6821347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fesoterodine acts as a prodrug and is converted to an active metabolite, 5-hydroxymethyl tolterodine (5-HMT); 5-HMT is responsible for fesoterodine&rsquo;s antimuscarinic activity and acts as a competitive antagonist of muscarinic receptors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Urinary bladder contractions are mediated by muscarinic receptors; fesoterodine inhibits the receptors in the bladder preventing symptoms of urgency and frequency.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6821349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: I.V.: 5-HMT: V",
"     <sub>",
"      d",
"     </sub>",
"     : 169 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 5-HMT: ~50% (primarily to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Fesoterodine is rapidly and extensively metabolized to its active metabolite (5-hydroxymethyl tolterodine; 5-HMT) by nonspecific esterases; 5-HMT is further metabolized via CYP2D6 and CYP3A4 to inactive metabolites.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 5-HMT: 52%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 5-HMT: ~5 hours; C",
"     <sub>",
"      max",
"     </sub>",
"     higher in poor CYP2D6 metabolizers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~70%; 16% as 5-HMT, ~53% as inactive metabolites); feces (7%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/53/28501/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapple C, Van Kerrebroeck P, Tubaro A, et al, &ldquo;Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects With Overactive Bladder,&rdquo;",
"      <i>",
"       Eur Urol",
"      </i>",
"      , 2007, 52(4):1204-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/53/28501/abstract-text/17651893/pubmed\" id=\"17651893\" target=\"_blank\">",
"        17651893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khullar V, Rovner ES, Dmochowski R, et al, &ldquo;Fesoterodine Dose Response in Subjects With Overactive Bladder Syndrome,&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 2008, 71(5):839-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/53/28501/abstract-text/18342923/pubmed\" id=\"18342923\" target=\"_blank\">",
"        18342923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Michel M, &ldquo;Fesoterodine: A Novel Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder Syndrome,&rdquo;",
"      <i>",
"       Expert Opin Pharmacother",
"      </i>",
"      , 2008, 9(10):1787-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/53/28501/abstract-text/18570610/pubmed\" id=\"18570610\" target=\"_blank\">",
"        18570610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nitti VW, Dmochowski R, Sand PK, et al, &ldquo;Efficacy, Safety and Tolerability of Fesoterodine for Overactive Bladder Syndrome,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2007, 178(5):2488-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/53/28501/abstract-text/17937959/pubmed\" id=\"17937959\" target=\"_blank\">",
"        17937959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9061 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28501=[""].join("\n");
var outline_f27_53_28501=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6788469\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821328\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821362\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821363\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821359\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821360\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821368\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821326\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821366\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821330\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821325\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821340\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821335\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821336\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299329\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6833846\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821344\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821331\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821332\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821334\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16355062\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821365\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321860\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992807\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821347\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821349\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9061\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9061|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/34/12836?source=related_link\">",
"      Fesoterodine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_53_28502="Megaloblastic marrow";
var content_f27_53_28502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Megaloblastic erythropoiesis - bone marrow aspirate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with megaloblastic anemia secondary to vitamin B12 deficiency. This field shows a predominance of megaloblastic erythroid precursors (black arrows), two giant metamyelocytes (red arrows) and a mitotic figure (blue arrow). (Wright-Giemsa).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28502=[""].join("\n");
var outline_f27_53_28502=null;
var title_f27_53_28503="Pathophysiology of cardiogenic pulmonary edema";
var content_f27_53_28503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of cardiogenic pulmonary edema",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/53/28503/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28503/contributors\">",
"     Duane S Pinto, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28503/contributors\">",
"     Robb D Kociol, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/53/28503/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28503/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/53/28503/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28503/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/53/28503/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiogenic pulmonary edema is a common and potentially fatal cause of acute respiratory distress. Cardiogenic pulmonary edema is most often a result of acute decompensated heart failure (ADHF). The clinical presentation is characterized by the development of dyspnea associated with the rapid accumulation of fluid within the lung's interstitial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alveolar spaces, which is the result of acutely elevated cardiac filling pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ADHF is most commonly due to left ventricular (LV) systolic or diastolic dysfunction, with or without additional cardiac pathology, such as coronary artery disease or valve abnormalities. However, a variety of conditions or events can cause cardiogenic pulmonary edema in the absence of heart disease, including primary fluid overload (eg, due to blood transfusion), severe hypertension, renal artery stenosis, and severe renal disease.",
"   </p>",
"   <p>",
"    Noncardiogenic pulmonary edema is a distinct clinical syndrome associated with diffuse filling of the alveolar spaces in the absence of elevated pulmonary capillary wedge pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/1\">",
"     1",
"    </a>",
"    ]. Focused history, physical examination, echocardiography, laboratory analysis and, in some cases, direct measurement of pulmonary capillary wedge pressure can be used to distinguish cardiogenic from noncardiogenic pulmonary edema, as well as from other causes of acute respiratory distress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link\">",
"     \"Noncardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Flash pulmonary edema is a term that is used to describe a particularly dramatic form of cardiogenic alveolar pulmonary edema. In flash pulmonary edema, the underlying pathophysiologic principles, etiologic triggers, and initial management strategies are similar to those of less severe ADHF, although there is a greater degree of urgency to the implementation of initial therapies and the search for triggering causes. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Precipitating factors'",
"    </a>",
"    below.) Often, flash pulmonary edema is related to a sudden rise in left-sided intracardiac filling pressures in the setting hypertensive urgency, acute ischemia, new onset tachyarrhythmia, or obstructive valvular disease. Flash pulmonary edema rarely occurs among patients with chronic dilated cardiomyopathies. In addition to standard therapies for cardiogenic pulmonary edema, this condition responds well to combined venous and arterial vasodilators such as intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    General issues related to the pathophysiology and etiology of cardiogenic pulmonary edema will be reviewed here. The evaluation and treatment of ADHF and the evaluation of the clinically stable patient with suspected heart failure (HF) are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiogenic pulmonary edema is characterized by increased transudation of protein-poor fluid into the pulmonary interstitium and alveolar spaces. The primary etiologic factor is a rapid and acute increase in left ventricular filling pressures and left atrial pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18273142\">",
"    <span class=\"h2\">",
"     Fluid transudation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid transudation is mediated by a rise in pulmonary capillary pressure that results from an increase in pulmonary venous and left atrial pressure. This occurs in the absence of a primary change in the permeability or integrity of the endothelial and epithelial layers of the pulmonary capillaries. The net result is filtration of protein-poor liquid across the pulmonary endothelium into the pulmonary interstitium and alveolar spaces, leading to decreased diffusing capacity, hypoxia, and shortness of breath [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The Starling relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid balance between the interstitium and vascular bed in the lung, as in other microcirculations, is determined by the Starling relationship, which predicts the net flow of liquid across a membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/3\">",
"     3",
"    </a>",
"    ]. This can be expressed in the following equation:",
"   </p>",
"   <p>",
"    &nbsp;Net filtration &nbsp;= &nbsp;(Lp x S) &nbsp; x &nbsp;",
"    <span class=\"nowrap\">",
"     (&Delta;",
"    </span>",
"    hydraulic pressure &nbsp; - &nbsp;",
"    <span class=\"nowrap\">",
"     &Delta;",
"    </span>",
"    oncotic pressure)",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; = &nbsp; (Lp x S) &nbsp; x &nbsp; [(Pcap &nbsp; - &nbsp; Pif) &nbsp; - &nbsp; s(&pi;cap &nbsp; - &nbsp; &pi;if)]",
"   </p>",
"   <p>",
"    where:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lp is the unit permeability (or porosity) of the capillary wall",
"     </li>",
"     <li>",
"      S is the surface area available for fluid movement",
"     </li>",
"     <li>",
"      Pcap and Pif are the capillary and interstitial fluid hydraulic pressures",
"     </li>",
"     <li>",
"      &pi;cap and &pi;if are the capillary and interstitial fluid oncotic pressures; the interstitial oncotic pressure is derived primarily from filtered plasma proteins and to a lesser degree proteoglycans in the interstitium.",
"     </li>",
"     <li>",
"      s represents the reflection coefficient of proteins across the capillary wall (with values ranging from 0 if completely permeable to 1 if completely impermeable).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In normal microvessels, there is ongoing filtration of a small amount of low protein liquid. In cardiogenic pulmonary edema, the increase in transcapillary filtration is generally attributed to elevation in pulmonary capillary pressure, although permeability of the capillary wall may also be affected (See",
"    <a class=\"local\" href=\"#H18273134\">",
"     'Pulmonary capillary stress failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Compensatory mechanisms, particularly activation of the renin-angiotensin and sympathetic nervous systems, result in tachycardia and an elevation in systemic vascular resistance (SVR) that may be deleterious in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tachycardia, which shortens the duration of diastole, impairs the ability of the left ventricle to fill.",
"     </li>",
"     <li>",
"      An elevated SVR increases left ventricular afterload (wall tension), increasing myocardial oxygen demand.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes can lead to a further increase in left ventricular end-diastolic pressure and more edema formation. To the degree that pulmonary edema results in hypoxia, there may be a further worsening of myocardial function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18273134\">",
"    <span class=\"h2\">",
"     Pulmonary capillary stress failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cardiogenic pulmonary edema is generally attributed to transudation of low protein fluid in response to high pulmonary capillary pressure, experimental studies have demonstrated that severe elevation in pulmonary capillary pressure can lead to increased permeability of the capillary wall and eventually stress failure of the blood-gas barrier at the capillary endothelial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alveolar epithelial layer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/4\">",
"     4",
"    </a>",
"    ]. Stress failure of pulmonary capillaries is manifest as high-permeability edema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alveolar hemorrhage. Pulmonary capillary stress failure may occur in some patients with flash pulmonary edema with abrupt severe increases in pulmonary capillary pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Precipitating factors'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of lymphatics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of accumulation of lung liquid at a given elevation in pulmonary capillary pressure is related to the functional capacity of the lymphatic vessels to remove the excess fluid, which varies from patient to patient and with the duration of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/6\">",
"     6",
"    </a>",
"    ]. With acute rises in pulmonary capillary pressure, the pulmonary lymphatics cannot rapidly increase the rate of fluid removal; as a result, pulmonary edema occurs at pulmonary capillary pressures as low as 18 mmHg. In contrast, patients with chronic heart failure, in whom the pulmonary capillary wedge pressure is persistently elevated, have increased lymphatic capacity and do not develop pulmonary edema until significantly higher pulmonary capillary pressures are reached.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREDISPOSING CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considering the etiologies of cardiogenic pulmonary edema, it is useful to distinguish the chronic cardiac conditions that predispose to episodes of pulmonary edema from the triggers that precipitate pulmonary edema.",
"   </p>",
"   <p>",
"    The chronic conditions that predispose to HF are presented in detail separately. For the purposes of this discussion, some of the more common conditions leading to heart failure and cardiogenic pulmonary edema (eg, left ventricular systolic and diastolic dysfunction) are reviewed briefly here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and causes of heart failure\", section on 'Predisposing conditions for HF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Systolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired LV contractility, resulting in reduced cardiac output, is the most common predisposing condition leading to cardiogenic pulmonary edema. LV systolic dysfunction itself has many causes, including the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coronary heart disease",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Valvular heart disease",
"     </li>",
"     <li>",
"      Idiopathic dilated cardiomyopathy.",
"     </li>",
"     <li>",
"      Toxins (eg, anthracyclines)",
"     </li>",
"     <li>",
"      Metabolic disorders (eg, hypothyroidism)",
"     </li>",
"     <li>",
"      Viral myocarditis (eg, Coxsackie B virus or echovirus infection).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decrease in forward flow caused by systolic dysfunction leads to activation of the renin-angiotensin-aldosterone and sympathetic nervous systems. The compensatory renal sodium and water retention induced by these adaptations ultimately result in pulmonary edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diastolic dysfunction refers to an increase in ventricular stiffness (reduced compliance) and impaired relaxation that impedes ventricular filling during diastole. It can be induced by chronic disorders, such as left ventricular hypertrophy of any etiology or hypertrophic and restrictive cardiomyopathies, and acutely with ischemia and acute hypertensive crisis. The net effect of diastolic dysfunction is an increase in end-diastolic pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the elevated end-diastolic pressure, additional factors that may promote the development of pulmonary edema in patients with diastolic dysfunction include concurrent systolic dysfunction, reduced diastolic coronary blood flow, resulting in subendocardial ischemia; and arrhythmia, particularly atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=see_link\">",
"     \"Pathophysiology of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not all cases of cardiogenic pulmonary edema in patients with normal ejection fraction are due primarily to intrinsic abnormalities of LV diastolic function. Other causes include volume overload (as in renal failure) and increased afterload (as in hypertensive crisis) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Volume overload'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15061766\">",
"     'Renovascular hypertension'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Left ventricular outflow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular outflow obstruction can be the result of critical aortic stenosis (including supravalvular and subvalvular stenosis), hypertrophic cardiomyopathy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe systemic hypertension. Chronic left ventricular outflow obstruction is associated with a hypertrophied left ventricular wall, which can produce diastolic and, over time, systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link\">",
"     \"Overview of hypertrophic cardiomyopathy management including treatment of special problems\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mitral stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral stenosis is generally the result of rheumatic heart disease. It is now less often seen in the United States, but is still a major cardiac problem in the third world. The chronic obstruction to atrial outflow leads to elevated left atrial pressures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of mitral stenosis\"",
"    </a>",
"    .) Mitral annular calcification is a rare cause of symptomatic mitral stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37801?source=see_link\">",
"     \"Mitral annular calcification\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typically slow progression of the disease allows gradual adaptation to the increased pressures and patients with mild to moderate degrees of stenosis are not typically symptomatic. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Role of lymphatics'",
"    </a>",
"    above.) However, conditions that cause an elevated heart rate and decreased diastolic filling time, such as poorly rate-controlled atrial fibrillation or exercise, can lead to acute elevations of left atrial pressures, and pulmonary edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18901?source=see_link\">",
"     \"Natural history of mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15061766\">",
"    <span class=\"h2\">",
"     Renovascular hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renovascular disease, particularly chronic hypertension due to renal artery stenosis, is associated with predisposing conditions as well as precipitating factors for pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Patients with renovascular disease may be predisposed to pulmonary edema because of diastolic dysfunction secondary to chronic hypertension and also from excess sodium and water retention secondary to activation of the renin-angiotensin system and associated renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An association between recurrent pulmonary edema and renovascular hypertension was first described by Pickering et al. who reported pulmonary edema in 13 of 55 patients with renovascular hypertension and azotemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/8\">",
"     8",
"    </a>",
"    ]. Flash pulmonary edema appears to be more common in patients with bilateral renal artery stenosis as compared to those with unilateral disease (eg, 41 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. The combination of bilateral renal artery stenosis and flash pulmonary edema has been named the Pickering syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Limited evidence is available on the efficacy of revascularization for this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=see_link\">",
"     \"Treatment of bilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PRECIPITATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of preexisting systolic or diastolic dysfunction, other disease entities or physiologic conditions may precipitate hemodynamic decompensation and promote the development of pulmonary edema (",
"    <a class=\"graphic graphic_table graphicRef50373 \" href=\"UTD.htm?41/29/42460\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Flash pulmonary edema is a term that is used to describe a particularly dramatic form of ADHF caused by acute increases in left ventricular diastolic pressure with rapid fluid accumulation in the pulmonary interstitial and alveolar spaces [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/5\">",
"     5",
"    </a>",
"    ]. This may occur in some patients with myocardial ischemia with or without myocardial infarction, acute severe mitral regurgitation, hypertensive crisis, acute aortic regurgitation, and stress-induced (takotsubo) cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33446?source=see_link\">",
"     \"Treatment of acute decompensated heart failure in acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of specific hypertensive emergencies\", section on 'Acute pulmonary edema'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=see_link\">",
"     \"Acute aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bilateral renal artery stenosis is a risk factor for flash pulmonary edema. (See",
"    <a class=\"local\" href=\"#H15061766\">",
"     'Renovascular hypertension'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16441511\">",
"    <span class=\"h2\">",
"     Hypertensive crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with cardiogenic pulmonary edema commonly present with systemic hypertension, which may be severe [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/17\">",
"     17",
"    </a>",
"    ]. Many of these patients have a preserved (normal or near normal) left ventricular ejection fraction. Excess afterload, instead of or in addition to fluid overload, may precipitate decompensation in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Myocardial ischemia/infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ADHF commonly have coronary artery disease with or without an acute coronary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/18\">",
"     18",
"    </a>",
"    ]. The acute onset of severe myocardial ischemia can lead to a sudden impairment in systolic and diastolic function, resulting in a decreased cardiac output, elevated filling pressures and the development of pulmonary edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With systolic dysfunction, there is less forward ejection, leading to increases in diastolic volume and diastolic pressure.",
"     </li>",
"     <li>",
"      With diastolic dysfunction, the enhanced stiffness of the myocardium raises diastolic pressure at any given diastolic volume. Even transient ischemia can exacerbate preexisting diastolic dysfunction, which is a common finding in patients with coronary artery disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=see_link\">",
"       \"Pathophysiology of diastolic heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myocardial ischemia may also precipitate acute valvular pathology, particularly mitral regurgitation. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Acute mitral regurgitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute aortic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abrupt onset of acute aortic regurgitation leads to a rapid rise in cardiac filling pressures due to the inability of the left ventricle to quickly adapt to the rapid increase in end-diastolic volume caused by the regurgitant blood. Acute valvular dysfunction can be seen in cases of endocarditis, aortic root dissection, complications associated with prosthetic valves and surgical technique, and spontaneous or traumatic rupture of the aortic leaflets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=see_link\">",
"     \"Acute aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of isolated, severe acute mitral regurgitation in adults is chordal rupture with or without associated myxomatous disease. Other causes of acute mitral valve incompetence include myocardial ischemia or infarction, resulting in papillary muscle rupture or papillary muscle displacement (previously known as papillary muscle dysfunction), endocarditis, which can lead to chordal rupture, and prosthetic valve dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who do not have chronic mitral regurgitation, the left atrium is usually not compliant. Regurgitant flow into a noncompliant left atrium leads to an increase in pressure that is conducted to the pulmonary circulation.",
"   </p>",
"   <p>",
"    Some patients with ischemic heart disease and left ventricular systolic dysfunction develop acute pulmonary edema without apparent cause. Some of these patients have mitral regurgitation, which may be mild at rest but is made substantially worse with exercise, often leading to dyspnea that requires cessation of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28503/abstract/19\">",
"     19",
"    </a>",
"    ]. This change can occur in the absence of detectable ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link&amp;anchor=H8#H8\">",
"     \"Ischemic mitral regurgitation\", section on 'Association with acute pulmonary edema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute left atrial outflow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute impairment of outflow from the left atrium to the LV can cause increased pulmonary pressures. Although uncommon, this can precipitate pulmonary edema. Causes of acute left atrial outflow impairment include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left atrial tumors (eg, myxoma). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link&amp;anchor=H3#H3\">",
"       \"Cardiac tumors\", section on 'Left atrial tumors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombosis of a prosthetic valve. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H8#H8\">",
"       \"Complications of prosthetic heart valves\", section on 'Valve obstruction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In chronic left atrial outflow impairment (eg, mitral stenosis or cor triatriatum), pulmonary edema is often precipitated when an elevated heart rate decreases the time for LV filling. Pulmonary edema may also be precipitated by an increased intravascular volume, as occurs with pregnancy or an increase in salt intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Volume overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume overload of the LV can be induced by any cause of increased intravascular volume (eg, primary sodium retention), and also by ventricular septal rupture or aortic insufficiency. Acute ventricular septal rupture is a complication of acute myocardial infarction (both anterior and inferior). Rupture occurs within five to seven days after the infarct. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link&amp;anchor=H10#H10\">",
"     \"Mechanical complications of acute myocardial infarction\", section on 'Rupture of the interventricular septum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13106144\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiogenic pulmonary edema is characterized by the development of dyspnea associated with the rapid accumulation of fluid within the lung's interstitial and alveolar spaces, which is the result of acutely elevated cardiac filling pressures (cardiogenic pulmonary edema). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiogenic pulmonary edema is characterized by increased transudation of protein-poor fluid into the pulmonary interstitium and alveolar spaces. The primary etiologic factor is a rapid and acute increase in left ventricular filling pressures and left atrial pressure, usually associated with a reduction in cardiac output. Fluid balance between the interstitium and vascular bed in the lung, as in other microcirculations, is determined by the Starling relationship, which predicts the net flow of liquid across a membrane. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic conditions that predispose to ADHF and resultant pulmonary edema include disorders causing systolic dysfunction, those causing diastolic dysfunction, causes of left ventricular outflow obstruction, and causes of mitral stenosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Predisposing conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Precipitating factors that promote development of cardiogenic pulmonary edema include myocardial ischemia or infarction, acute aortic regurgitation, acute mitral regurgitation, renovascular hypertension, acute left atrial outflow impairment, and other causes of volume overload. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Precipitating factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flash pulmonary edema is a term that is used to describe a dramatic form of ADHF, caused by an acute increase in left ventricular diastolic pressure as may occur with myocardial ischemia with or without myocardial infarction, acute severe mitral regurgitation, hypertensive crisis, acute aortic regurgitation, and stress-induced (takotsubo) cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Precipitating factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6167201\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Stanley Lewis for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/1\">",
"      Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med 2005; 353:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/2\">",
"      Gropper MA, Wiener-Kronish JP, Hashimoto S. Acute cardiogenic pulmonary edema. Clin Chest Med 1994; 15:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/3\">",
"      Chua TP, Coats AJ. The lungs in chronic heart failure. Eur Heart J 1995; 16:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/4\">",
"      West JB, Mathieu-Costello O. Vulnerability of pulmonary capillaries in heart disease. Circulation 1995; 92:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/5\">",
"      Rimoldi SF, Yuzefpolskaya M, Allemann Y, Messerli F. Flash pulmonary edema. Prog Cardiovasc Dis 2009; 52:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/6\">",
"      Szidon JP. Pathophysiology of the congested lung. Cardiol Clin 1989; 7:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/7\">",
"      Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/8\">",
"      Pickering TG, Herman L, Devereux RB, et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularisation. Lancet 1988; 2:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/9\">",
"      Messina LM, Zelenock GB, Yao KA, Stanley JC. Renal revascularization for recurrent pulmonary edema in patients with poorly controlled hypertension and renal insufficiency: a distinct subgroup of patients with arteriosclerotic renal artery occlusive disease. J Vasc Surg 1992; 15:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/10\">",
"      Missouris CG, Belli AM, MacGregor GA. \"Apparent\" heart failure: a syndrome caused by renal artery stenoses. Heart 2000; 83:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/11\">",
"      Planken II, Rietveld AP. Rapid onset pulmonary edema (flash edema) in renal artery stenosis. Neth J Med 1998; 52:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/12\">",
"      Vasan RS, Benjamin EJ. Diastolic heart failure--no time to relax. N Engl J Med 2001; 344:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/13\">",
"      Bloch MJ, Trost DW, Pickering TG, et al. Prevention of recurrent pulmonary edema in patients with bilateral renovascular disease through renal artery stent placement. Am J Hypertens 1999; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/14\">",
"      Messerli FH, Bangalore S, Makani H, et al. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome. Eur Heart J 2011; 32:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/15\">",
"      Pelta A, Andersen UB, Just S, B&aelig;kgaard N. Flash pulmonary edema in patients with renal artery stenosis--the Pickering Syndrome. Blood Press 2011; 20:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/16\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/17\">",
"      Weintraub NL, Collins SP, Pang PS, et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation 2010; 122:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/18\">",
"      Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol 2009; 53:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28503/abstract/19\">",
"      Pi&eacute;rard LA, Lancellotti P. The role of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema. N Engl J Med 2004; 351:1627.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3487 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28503=[""].join("\n");
var outline_f27_53_28503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13106144\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18273142\">",
"      Fluid transudation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The Starling relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18273134\">",
"      Pulmonary capillary stress failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of lymphatics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREDISPOSING CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Left ventricular outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15061766\">",
"      Renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PRECIPITATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16441511\">",
"      Hypertensive crisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Myocardial ischemia/infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute left atrial outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Volume overload",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13106144\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6167201\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3487\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3487|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/29/42460\" title=\"table 1\">",
"      Precip factors ADHF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=related_link\">",
"      Acute aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=related_link\">",
"      Establishing the diagnosis of renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37801?source=related_link\">",
"      Mitral annular calcification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18901?source=related_link\">",
"      Natural history of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=related_link\">",
"      Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=related_link\">",
"      Pathophysiology of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=related_link\">",
"      Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33446?source=related_link\">",
"      Treatment of acute decompensated heart failure in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=related_link\">",
"      Treatment of bilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=related_link\">",
"      Treatment of specific hypertensive emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_53_28504="Diagnosis and management of foreign bodies of the outer ear";
var content_f27_53_28504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and management of foreign bodies of the outer ear",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/53/28504/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28504/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28504/contributors\">",
"     Aderonke Ojo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/53/28504/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28504/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/53/28504/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28504/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/53/28504/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H903746\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embedded earrings in the earlobe or cartilaginous portions of the pinna and external auditory canal (EAC) foreign bodies are common problems encountered by primary care and emergency physicians. Physical examination provides the diagnosis in most patients.",
"   </p>",
"   <p>",
"    Successful removal of foreign bodies of the pinna requires appropriate analgesia using local anesthesia or procedural sedation. Local infection and perichondritis frequently complicate these foreign bodies.",
"   </p>",
"   <p>",
"    Proper restraint, adequate illumination, and appropriate equipment are essential for successful extraction of foreign bodies of the external auditory canal. Complex EAC foreign bodies (eg, button batteries, objects up against the tympanic membrane, or those associated with injury to the tympanic membrane or middle ear) warrant prompt referral to an otolaryngologist.",
"   </p>",
"   <p>",
"    This topic discusses the diagnosis and management of foreign bodies of the outer ear. The evaluation and management of lacerations of the ear are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6137?source=see_link\">",
"     \"Assessment and management of auricle (ear) lacerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19482341\">",
"    <span class=\"h1\">",
"     FOREIGN BODIES OF THE PINNA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H903865\">",
"    <span class=\"h2\">",
"     Relevant anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foreign bodies of the pinna usually arise from embedded pierced earrings. These may be located in the earlobe or the cartilaginous portions of the pinna (",
"    <a class=\"graphic graphic_figure graphicRef57847 \" href=\"UTD.htm?7/57/8081\">",
"     figure 1",
"    </a>",
"    ). Local contact dermatitis to gold-plated or metal alloy studs, poor hygiene, and constant pressure caused by fixing clips create local swelling at the piercing site. Subsequently, skin ischemia, inflammation, and decubitus ulcer formation develop along with penetration of a portion or the entire earring into the pinna [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H903858\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embedded earrings are most common in girls under 10 years of age and young adolescents who are less likely to perform appropriate hygiene and more likely to frequently handle the earring [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H903851\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embedded earrings are diagnosed based upon clinical features in patients who have recently undergone ear piercing. Patients with embedded earrings commonly present with ear pain, swelling, redness, and purulent drainage from the piercing site [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/2\">",
"     2",
"    </a>",
"    ]. In such cases, the earring may be palpable, especially when embedded in the earlobe. However, palpation of the external ear is often exquisitely painful. Alternatively, plain radiographs can confirm the diagnosis when the earring is not visible.",
"   </p>",
"   <p>",
"    Piercing through the cartilage of the helix or fossa triangularis can lead to infection, perichondritis, and permanent disfigurement (",
"    <a class=\"graphic graphic_picture graphicRef86319 \" href=\"UTD.htm?12/40/12929\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef86320 \" href=\"UTD.htm?20/29/20947\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13832065\">",
"    <span class=\"h2\">",
"     Removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jewelry portions that have migrated into the subcutaneous tissues should be removed promptly to avoid infection. Analgesia for this procedure is typically accomplished by local infiltration or field block. In younger patients, procedural sedation may be needed. Local anesthesia of the ear and procedural sedation in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6137?source=see_link&amp;anchor=H28089301#H28089301\">",
"     \"Assessment and management of auricle (ear) lacerations\", section on 'Anesthesia and analgesia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H1683215#H1683215\">",
"     \"Procedural sedation in children outside of the operating room\", section on 'Performing procedural sedation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Equipment",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       Povidone iodine",
"      </a>",
"      solution",
"     </li>",
"     <li>",
"      Sterile gauze",
"     </li>",
"     <li>",
"      Two mosquito hemostats",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The steps in removing an embedded earring depend upon what part of the earring or post is embedded and are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prepare the wound site with iodine and use sterile technique in the event that an incision is necessary for removal.",
"     </li>",
"     <li>",
"      Provide local anesthesia. Procedural sedation may be necessary in young or otherwise uncooperative patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6137?source=see_link&amp;anchor=H28089301#H28089301\">",
"       \"Assessment and management of auricle (ear) lacerations\", section on 'Anesthesia and analgesia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H1683215#H1683215\">",
"       \"Procedural sedation in children outside of the operating room\", section on 'Performing procedural sedation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Embedded earring or post backing (clip) with earring front or post visible:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Apply posterior pressure to the decorative front of the earring or post, until the backing or clip becomes visible behind the pinna.",
"     </li>",
"     <li>",
"      Clamp a hemostat to the backing (clip) and disengage it from the earring or post by pulling the clip posteriorly while holding the earring or post anteriorly.",
"     </li>",
"     <li>",
"      If the above technique fails, make a small incision on the",
"      <strong>",
"       posterior",
"      </strong>",
"      portion of the pinna over the piercing site and gently spread the skin using a hemostat until the clip comes into view.",
"     </li>",
"     <li>",
"      Clamp the hemostat to the clip and remove it from the earring or post as described above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Embedded earring front or post with backing (clip) visible:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Push the earring or post backing (clip) anteriorly until the decorative front or post is visible.",
"     </li>",
"     <li>",
"      Clamp a hemostat to the decorative earring front or post.",
"     </li>",
"     <li>",
"      Clamp a hemostat to the backing (clip) and disengage it from the earring front or post as described above.",
"     </li>",
"     <li>",
"      Alternatively, make a small incision with a #11 blade scalpel on the",
"      <strong>",
"       posterior",
"      </strong>",
"      portion of the pinna over the piercing site and gently spread the skin using a hemostat. Grasp and remove the earring (",
"      <a class=\"graphic graphic_picture graphicRef88538 \" href=\"UTD.htm?28/48/29443\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Embedded earring front or post and backing (clip) with nothing visible:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Make a small incision on the",
"      <strong>",
"       posterior",
"      </strong>",
"      portion of the pinna over the piercing site and gently spread the skin using a hemostat until the backing (clip) comes into view.",
"     </li>",
"     <li>",
"      Grasp the backing and then proceed as described for an embedded earring front or post with backing (clip) visible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dress the wound with antibiotic ointment (eg, triple antibiotic ointment) and allow it to heal by secondary intention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13832468\">",
"    <span class=\"h2\">",
"     Treatment of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Piercing of the cartilaginous portion of the pinna has been associated with perichondritis and chondritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Signs of perichondritis or chondritis in patients with an embedded earring are similar and include pain, swelling and erythema of the overlying skin. Consultation with an otolaryngologist is advised. Fluctuant swelling indicates an abscess that must be drained and is typically associated with chondritis;",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    is the pathogen in up to 95 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/7\">",
"     7",
"    </a>",
"    ]. Antibiotic options should cover",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    and methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    and include oral fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ) in adolescents and adults and parenteral antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ) in children. Even with timely and proper antibiotic treatment, these infections may result in cartilage necrosis and cosmetic disfigurement (",
"    <a class=\"graphic graphic_picture graphicRef82036 \" href=\"UTD.htm?28/40/29314\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After removal of embedded earrings in the earlobe, local care and topical antibiotics are typically sufficient to treat swelling and redness that is confined to the immediate piercing site. However, extensive redness or swelling warrants treatment as previously described for perichondritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19482771\">",
"    <span class=\"h1\">",
"     FOREIGN BODIES OF THE EXTERNAL AUDITORY CANAL (EAC)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19482348\">",
"    <span class=\"h2\">",
"     Relevant anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ear canal is divided into an outer cartilaginous and inner bony portion (",
"    <a class=\"graphic graphic_figure graphicRef63141 \" href=\"UTD.htm?32/32/33285\">",
"     figure 2",
"    </a>",
"    ) and is innervated by the facial, glossopharyngeal, vagus nerves. Most of the canal is cartilaginous in young children. As the bony tympanic ring grows, the external auditory canal becomes roughly one-third cartilaginous and two-thirds bony with a narrow isthmus separating the two zones. The cartilaginous portion is superficial and has thick lining skin, subcutaneous tissue and hair structures. The skin of the deeper bony part of the ear canal is thin, tightly attached to underlying periosteum and free of hair. Manipulation of foreign bodies in the deep, hairless portion of the ear canal can lead to pain and bleeding, while the superficial portion is less sensitive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29168905\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most aural foreign bodies are found in children six years of age and younger with a smaller portion occurring in older children and special needs adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Children with irritating conditions of the ear (eg, cerumen impaction, otitis externa, or otitis media) or those with pica are predisposed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FB is frequently located in the right ear, corresponding to the predominant handedness in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/12\">",
"     12",
"    </a>",
"    ]. The most common objects removed include beads, pebbles, tissue paper, small toys, popcorn kernels, and insects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/10\">",
"     10",
"    </a>",
"    ]. The type of foreign bodies varies by culture and economic status (eg, beads and toys in developed countries; seeds and stones in developing countries) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8360855\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with foreign bodies of the external auditory canal (EAC) are frequently asymptomatic. Common presentations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Caregiver concern of EAC foreign body based upon witnessing placement or seeing something in the ear",
"     </li>",
"     <li>",
"      Incidental finding during routine otoscopy",
"     </li>",
"     <li>",
"      Decreased hearing or ear pain",
"     </li>",
"     <li>",
"      Purulent or bloody ear drainage (rare)",
"     </li>",
"     <li>",
"      Chronic cough or hiccups (rare) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/10,15\">",
"       10,15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Visualization of a foreign body in the EAC on otoscopy confirms the diagnosis. The other ear and both nostrils should also be examined closely for additional foreign bodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8360863\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, history and visualization by otoscopy are sufficient to identify a foreign body in the EAC and to exclude other diagnoses. Other lesions may rarely mimic foreign bodies of the ear canal as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A congenital cholesteatoma (abnormal accumulation of squamous epithelium within the middle ear and mastoid) may have the appearance of a round white foreign body (",
"      <a class=\"graphic graphic_picture graphicRef72870 graphicRef73085 \" href=\"UTD.htm?31/53/32598\">",
"       picture 5A-B",
"      </a>",
"      ). It typically is seen in the anterosuperior quadrant of the ear drum and is located within the middle ear. Palpation with a probe during otomicroscopy can differentiate a cholesteatoma from a foreign body when otoscopy is not definitive.",
"     </li>",
"     <li>",
"      In the unusual circumstance in which the foreign body causes ear drainage, other causes of otorrhea warrant consideration (",
"      <a class=\"graphic graphic_table graphicRef68061 \" href=\"UTD.htm?20/12/20684\">",
"       table 1",
"      </a>",
"      ). The most common of these is acute otitis media. History of ear pain and fever and physical examination demonstrating a clear or whitish discharge from the ear strongly suggest acute otitis media with tympanic membrane perforation. Suction of the drainage and visualization using otoscopy or otomicroscopy may also be helpful. Evaluation and diagnosis of other causes of otorrhea are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24728?source=see_link\">",
"       \"Evaluation of otorrhea (ear discharge) in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19482355\">",
"    <span class=\"h2\">",
"     Removal",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19482363\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of foreign body determines the timing for removal. Button batteries, live insects and penetrating foreign bodies warrant urgent removal for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Button batteries",
"      </strong>",
"      &ndash; Button batteries are found in toys, hearing aids, and household electronics. Once in the external auditory canal (EAC), they cause destruction because of strong electrical currents (rather than leakage of battery contents) and pressure necrosis. Maximum destruction typically occurs at the negative battery pole because electrolysis at that site generates hydroxide ions which cause alkaline tissue necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/16\">",
"       16",
"      </a>",
"      ]. Damage to the ear canal skin, tympanic membrane, facial nerve, and ossicles have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]. Permanent hearing loss has also been described.",
"     </li>",
"     <li>",
"      <strong>",
"       Insects",
"      </strong>",
"      &ndash; A variety of insects may take up temporary residence in the EAC (",
"      <a class=\"graphic graphic_picture graphicRef86324 \" href=\"UTD.htm?20/8/20608\">",
"       picture 6",
"      </a>",
"      ). Cockroaches are most commonly found, especially among inner city children, as they prefer warm, dark environments. A live insect moving in a child&rsquo;s ear canal can cause considerable discomfort and occasionally may damage the tympanic membrane and middle ear [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/19\">",
"       19",
"      </a>",
"      ]. Insects should be killed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       mineral oil",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/20\">",
"       20",
"      </a>",
"      ], ethanol or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/21\">",
"       21",
"      </a>",
"      ] prior to attempted removal to prevent excess insect movement during retrieval.",
"     </li>",
"     <li>",
"      <strong>",
"       Penetrating foreign bodies",
"      </strong>",
"      &ndash; Foreign bodies that might have penetrated the tympanic membrane and caused damage to middle ear structures require immediate attention. Cotton applicators (Q-tips&reg;), pencil points (",
"      <a class=\"graphic graphic_picture graphicRef86325 \" href=\"UTD.htm?11/26/11682\">",
"       picture 7",
"      </a>",
"      ), tree branches and hair pins are frequent culprits [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Pain, vertigo, nystagmus, ataxia, otorrhea, facial nerve paralysis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hearing loss are worrisome signs that warrant prompt consultation with an otolaryngologist. Weber and Rinne tuning fork tests help to identify hearing loss and can often differential a conductive loss (from tympanic membrane or ossicular disruption) from a sensory-neural loss (from damage to inner ear structures) (",
"      <a class=\"graphic graphic_table graphicRef74212 \" href=\"UTD.htm?13/29/13787\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef58032 \" href=\"UTD.htm?40/5/41043\">",
"       figure 3",
"      </a>",
"      ). The clinical features and management of middle ear trauma is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link&amp;anchor=H7#H7\">",
"       \"Evaluation and management of middle ear trauma\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link&amp;anchor=H17#H17\">",
"       \"Evaluation and management of middle ear trauma\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For other EAC foreign bodies (eg, round beads, paper, or foam rubber) removal can be deferred until necessary equipment and personnel are available as long as the patient is asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19482370\">",
"    <span class=\"h3\">",
"     Indications for consultation or referral to a specialist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent referral to an otolaryngologist",
"    <strong>",
"     prior",
"    </strong>",
"    to any removal attempts is indicated for patients with the following external auditory canal (EAC) foreign bodies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Button battery",
"     </li>",
"     <li>",
"      Potentially penetrating foreign bodies (eg, pencil, bobby pin, cotton-tipped applicators)",
"     </li>",
"     <li>",
"      Foreign body with evidence of injury to the EAC, tympanic membrane, or middle ear as indicated by otorrhea, vestibular symptoms (eg, nausea, vomiting, nystagmus, vertigo, or ataxia), or marked pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elective referral to an otolaryngologist within a few days is warranted for asymptomatic patients with the following types of EAC foreign bodies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glass or other sharp-edged foreign body",
"     </li>",
"     <li>",
"      Spherical or other foreign body that is tightly wedged in the medial EAC",
"     </li>",
"     <li>",
"      Foreign body that is up against the tympanic membrane",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon large case series, successful removal by other clinicians is unlikely in these instances and attempts may potentially cause complications such as ear canal laceration, tympanic membrane perforation, middle ear damage, or conversion of an easily removable foreign body to one that requires advanced techniques or general anesthesia for extraction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/10,24-26\">",
"     10,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, referral is warranted if the EAC foreign body is not easily removed upon the first attempt or in settings that lack proper instrumentation or staff available to restrain or sedate an uncooperative patient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many external auditory canal (EAC) foreign bodies can be removed in an emergency department or primary care provider&rsquo;s office using commonly available instruments (eg, irrigation setup, headlight without magnification, otoscope, alligator or bayonet forceps, or plastic or metal cerumen curette) as long as adequate restraint is assured [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/25,27,28\">",
"     25,27,28",
"    </a>",
"    ]. As an example, successful removal of EAC foreign bodies such as paper, cotton, erasers, Silly Putty&reg; occurred in 85 to 97 percent of cases in one review from a children&rsquo;s hospital emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/25\">",
"     25",
"    </a>",
"    ]. Success rates were highest for insects and superficial EAC foreign bodies that were easily grasped or manipulated in children older than four years of age.",
"   </p>",
"   <p>",
"    If otomicroscopy, proper equipment, and sufficient personnel are available, then successful removal of EAC foreign bodies by experienced clinicians, other than otolaryngologists, is enhanced, even for some complex foreign bodies. As an example, the availability of a dedicated otomicroscope in an inner city emergency department was associated with successful extraction of 76 percent of foreign bodies in 85 children, including those touching the tympanic membrane, present for more than 24 hours, or that failed prior attempts at removal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19482377\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1372265\">",
"    <span class=\"h4\">",
"     Irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;This technique is used for small inorganic objects or insects. Irrigation is often better tolerated than instrumentation and does not require direct visualization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/4\">",
"     4",
"    </a>",
"    ]. However, this technique is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in patients with tympanostomy tubes or perforated tympanic membranes and for the removal of vegetable matter (eg, a bean) or button batteries. Vegetable matter swells as it absorbs water, leading to further obstruction. Irrigation of a button battery enhances current flow and increases the potential for caustic injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Equipment",
"      </strong>",
"      &ndash; The following equipment should be assembled [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/30\">",
"       30",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      20 to 50 mL syringe",
"     </li>",
"     <li>",
"      Irrigation solution at body temperature (eg, luke-warm tap water, warmed sterile water or normal saline)",
"     </li>",
"     <li>",
"      Plastic butterfly needle tubing or 14- to 16- gauge plastic intravenous catheter",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       Mineral oil",
"      </a>",
"      , 95 percent ethanol, or 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      (to kill live insects); ethanol should be avoided in patients with a perforated tympanic membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Alternatively an electronic ear syringe with tips specifically designed for ear irrigation may be substituted. In contrast, dental irrigation devices should",
"      <strong>",
"       not",
"      </strong>",
"      be used because they produce an excessively forceful water stream that can cause tympanic membrane and middle ear damage [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Technique",
"      </strong>",
"      &ndash; Irrigation is performed as follows [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/30\">",
"       30",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Perform otoscopy to ensure that the tympanic membrane is intact and that tympanostomy tubes are",
"      <strong>",
"       not",
"      </strong>",
"      present.",
"     </li>",
"     <li>",
"      Place the patient in a supine position with the affected ear up and restrain as needed using a papoose (",
"      <a class=\"graphic graphic_picture graphicRef86352 \" href=\"UTD.htm?27/24/28032\">",
"       picture 8",
"      </a>",
"      ) or sheet wrap (eg young children or older patients with intellectual disability). Cooperative older patients may lie on a stretcher with the head up 30 to 90 degrees or remain seated in a chair.",
"     </li>",
"     <li>",
"      If removing an insect, instill",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       mineral oil",
"      </a>",
"      , 95 percent ethanol, or 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      to kill it prior to irrigation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Place a towel, chuck, or basin under the patient&rsquo;s head to catch the irrigant solution as it flows out of the ear.",
"     </li>",
"     <li>",
"      Place the catheter or plastic tubing approximately 1 to 1.5 cm into the EAC.",
"     </li>",
"     <li>",
"      Direct the irrigation stream along the posterior and superior margin of the EAC (",
"      <a class=\"graphic graphic_figure graphicRef86341 \" href=\"UTD.htm?10/56/11140\">",
"       figure 4",
"      </a>",
"      ) and briskly depress the syringe. Repeat until the foreign body is expelled.",
"     </li>",
"     <li>",
"      In some instances, the object is moved towards the auditory meatus but still requires extraction by instrumentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1372407\">",
"    <span class=\"h4\">",
"     Instrumentation under direct visualization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instrumentation permits external auditory canal (EAC) foreign body removal under direct visualization and examination of the tympanic membrane and EAC after removal. Adequate restraint, appropriate illumination, and proper equipment are essential to success. Instrumentation can be painful and frequently warrants procedural sedation in young children or other uncooperative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Equipment",
"      </strong>",
"      &ndash; The specific instruments required depend upon the type of foreign body (",
"      <a class=\"graphic graphic_picture graphicRef86351 \" href=\"UTD.htm?19/30/19940\">",
"       picture 9",
"      </a>",
"      ). The following list provides the range of equipment that is frequently used to remove EAC foreign bodies [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/30\">",
"       30",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Headlight or operating microscope &ndash; These light sources free the operator to brace both hands again the head, enhancing safety and are preferred (",
"      <a class=\"graphic graphic_picture graphicRef86350 \" href=\"UTD.htm?35/31/36351\">",
"       picture 10",
"      </a>",
"      ); an operating head otoscope is acceptable but provides less optimal control during the procedure.",
"     </li>",
"     <li>",
"      Ear speculum &ndash; Although not used for superficial EAC foreign bodies, a metal operating ear speculum directs light into the EAC and helps protect the lining from injury when retrieving objects that are deep within the EAC (",
"      <a class=\"graphic graphic_picture graphicRef86350 \" href=\"UTD.htm?35/31/36351\">",
"       picture 10",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Alligator forceps (",
"      <a class=\"graphic graphic_picture graphicRef86351 \" href=\"UTD.htm?19/30/19940\">",
"       picture 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gruenwald bayonet nasal dressing or Lucae forceps",
"     </li>",
"     <li>",
"      Schuknecht foreign body extractor (",
"      <a class=\"graphic graphic_picture graphicRef86356 \" href=\"UTD.htm?0/11/179\">",
"       picture 11",
"      </a>",
"      ) with suction tubing attached to wall suction. A similar device may be constructed by cutting a five to six cm length of respiratory suction catheter of a width that is slightly less than the diameter of the foreign body. The cut should be curved to permit better attachment of the round foreign body.",
"     </li>",
"     <li>",
"      Right-angle ball or Day hook (",
"      <a class=\"graphic graphic_picture graphicRef86351 \" href=\"UTD.htm?19/30/19940\">",
"       picture 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Plastic or metal cerumen curette",
"     </li>",
"     <li>",
"      Cyanoacrylate glue and wood or plastic swab stick",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       Mineral oil",
"      </a>",
"      , 95 percent ethanol, or 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      (to kill live insects; ethanol should be avoided in patients with a perforated tympanic membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/21\">",
"       21",
"      </a>",
"      ])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Techniques",
"      </strong>",
"      &ndash; The procedure is performed with specific instrumentation determined by the type of foreign body as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Place the patient in a supine position with the affected ear up.",
"     </li>",
"     <li>",
"      Restrain (",
"      <a class=\"graphic graphic_picture graphicRef86352 \" href=\"UTD.htm?27/24/28032\">",
"       picture 8",
"      </a>",
"      ) and, if needed for pain control and safety, sedate the patient.",
"     </li>",
"     <li>",
"      If removing an insect, instill",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       mineral oil",
"      </a>",
"      , ethanol, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      to kill it prior to removal with alligator forceps (",
"      <a class=\"graphic graphic_figure graphicRef86353 \" href=\"UTD.htm?12/2/12323\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Soft objects (eg, foam rubber or paper), those with protruding surfaces or irregular edges, and insects may be removed with alligator or Adson bayonet forceps (",
"      <a class=\"graphic graphic_figure graphicRef86354 \" href=\"UTD.htm?14/28/14787\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Objects that are round or breakable can be removed using a right-angle hook, angled wire loop, or angled cerumen curette that is slowly advanced beyond the object and carefully withdrawn (",
"      <a class=\"graphic graphic_figure graphicRef86355 \" href=\"UTD.htm?41/42/42658\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Freely mobile spherical objects are best removed with suction using a Schuknecht foreign body extractor (",
"      <a class=\"graphic graphic_picture graphicRef86356 \" href=\"UTD.htm?0/11/179\">",
"       picture 11",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef86357 \" href=\"UTD.htm?4/6/4195\">",
"       figure 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cyanoacrylate adhesive (eg, Super glue&trade;) has been used to remove wedged, smooth, round foreign bodies [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/33\">",
"       33",
"      </a>",
"      ]. The glue is applied to the blunt end of a cotton swab and then introduced into the ear canal. This technique requires the child to remain still while the glue dries (approximately 60 seconds) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/34\">",
"       34",
"      </a>",
"      ]. Care must be taken to avoid contact between the glue and the external auditory canal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2249451\">",
"    <span class=\"h4\">",
"     Cyanoacrylate glue occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanoacrylate glues (eg, Super glue&trade;) that have been instilled in the ear can be removed by applying acetone soaked cotton balls to the glue mass for 5 to 10 minutes until debonding from the skin has occurred followed by gentle extraction with alligator or bayonet forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/35\">",
"     35",
"    </a>",
"    ]. If acetone is not available, 3 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    is an alternative solvent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1372905\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;External auditory canal abrasion or laceration is the most common complication of foreign body removal and occurs in up to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/25,37,38\">",
"     25,37,38",
"    </a>",
"    ]. The risk of this complication is increased in patients who undergo multiple attempts at foreign body removal. Treatment consists of topical antibiotic ear drops (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    otic drops).",
"   </p>",
"   <p>",
"    Tympanic membrane perforation and middle ear damage have been reported but occur much less commonly. These more serious complications are associated with complex foreign bodies, especially button batteries and warrant prompt consultation with an otolaryngologist [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/16,37\">",
"     16,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tearing or abrasion of the tympanic membrane has been described following removal of cyanoacrylate glues from the external auditory canal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28504/abstract/35\">",
"     35",
"    </a>",
"    ]. Tearing of the tympanic membrane may be more common when appropriate solvents (eg, acetone) are not used. (See",
"    <a class=\"local\" href=\"#H2249451\">",
"     'Cyanoacrylate glue occlusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/57/10130?source=see_link\">",
"       \"Patient information: Removing objects stuck in the ear (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19482384\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foreign bodies of the pinna usually arise from embedded pierced earrings. These may be located in the earlobe or the cartilaginous portions of the pinna (",
"      <a class=\"graphic graphic_figure graphicRef57847 \" href=\"UTD.htm?7/57/8081\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H903865\">",
"       'Relevant anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with embedded earrings commonly present with ear pain, swelling, redness, and purulent drainage from the piercing site. On inspection, the earring clip behind the pinna is typically not seen while the post and decorative portion of the earring is often visible. In extreme cases, the entire earring may not be visualized. (See",
"      <a class=\"local\" href=\"#H903851\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Jewelry portions that have migrated into the subcutaneous tissues should be removed promptly to avoid infection. Analgesia for this procedure is typically accomplished by local infiltration or field block. In younger patients, procedural sedation may be needed. The technique for removal is described. (See",
"      <a class=\"local\" href=\"#H13832065\">",
"       'Removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perichondritis and chondritis may complicate pinna foreign bodies, especially for piercings through cartilage. When present, these infections warrant systemic antibiotics with activity against",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      and",
"      <em>",
"       Pseudomonas aeruginosa",
"      </em>",
"      and consultation with an otolaryngologist is advised. (See",
"      <a class=\"local\" href=\"#H13832468\">",
"       'Treatment of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Foreign bodies of the external ear canal (EAC) frequently occur in children six years of age and younger and consist of a variety of objects including round beads, pebbles, tissue paper, small toys, and insects. (See",
"      <a class=\"local\" href=\"#H29168905\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with foreign bodies of the external auditory canal (EAC) are frequently asymptomatic. Visualization of a foreign body in the EAC on otoscopy confirms the diagnosis. The other ear and both nostrils should also be examined closely for additional foreign bodies. In most patients, clinical findings are sufficient to identify a foreign body in the EAC and to exclude other diagnoses. (See",
"      <a class=\"local\" href=\"#H8360855\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8360863\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Button batteries in the EAC as well as penetrating foreign bodies or those associated with injury to the EAC, tympanic membrane, or middle ear warrant urgent removal by an otolaryngologist.",
"     </li>",
"     <li>",
"      Elective referral to an otolaryngologist is warranted for asymptomatic patients with EAC foreign bodies that are glass or sharp-edged, spherical and tightly wedged, or up against the tympanic membrane or when clinicians lack proper instrumentation or personnel to restrain or sedate an uncooperative patient. (See",
"      <a class=\"local\" href=\"#H19482370\">",
"       'Indications for consultation or referral to a specialist'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With adequate illumination, proper equipment, and sufficient personnel, many EAC foreign bodies can be removed by clinicians other than otolaryngologists. Techniques for removal are described. (See",
"      <a class=\"local\" href=\"#H19482377\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/1\">",
"      Fijakowska M, Pisera P, Kasielska A, Antoszewski B. Should we say NO to body piercing in children? Complications after ear piercing in children. Int J Dermatol 2011; 50:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/2\">",
"      de San Lazaro C, Jackson RH. Vanishing earrings. Arch Dis Child 1986; 61:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/3\">",
"      Timm N, Iyer S. Embedded earrings in children. Pediatr Emerg Care 2008; 24:31.",
"     </a>",
"    </li>",
"    <li>",
"     Martinez NJ, Friedman MJ. External ear procedures. In: Textbook of Pediatric Emergency Procedures, 2nd, King C, Henretig FM.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2008. p.593.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/5\">",
"      Sandhu A, Gross M, Wylie J, et al. Pseudomonas aeruginosa necrotizing chondritis complicating high helical ear piercing case report: clinical and public health perspectives. Can J Public Health 2007; 98:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/6\">",
"      Stewart GM, Thorp A, Brown L. Perichondritis--a complication of high ear piercing. Pediatr Emerg Care 2006; 22:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/7\">",
"      Fisher CG, Kacica MA, Bennett NM. Risk factors for cartilage infections of the ear. Am J Prev Med 2005; 29:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/8\">",
"      Marin JR, Trainor JL. Foreign body removal from the external auditory canal in a pediatric emergency department. Pediatr Emerg Care 2006; 22:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/9\">",
"      Weiser M, Levy A, Neuman M. Ear stuffing: an unusual form of self-mutilation. J Nerv Ment Dis 1993; 181:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/10\">",
"      Ansley JF, Cunningham MJ. Treatment of aural foreign bodies in children. Pediatrics 1998; 101:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/11\">",
"      Das SK. Aetiological evaluation of foreign bodies in the ear and nose. J Laryngol Otol 1984; 98:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/12\">",
"      Peridis S, Athanasopoulos I, Salamoura M, et al. Foreign bodies of the ear and nose in children and its correlation with right or left handed children. Int J Pediatr Otorhinolaryngol 2009; 73:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/13\">",
"      Fasunla AJ, Ogunleye OO, Ijaduola TG. Healthcare givers' skill and foreign bodies in the ears of children in the tropics. Int J Pediatr Otorhinolaryngol 2007; 71:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/14\">",
"      Mukherjee A, Haldar D, Dutta S, et al. Ear, nose and throat foreign bodies in children: a search for socio-demographic correlates. Int J Pediatr Otorhinolaryngol 2011; 75:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/15\">",
"      Lossos IS, Breuer R. A rare case of hiccups. N Engl J Med 1988; 318:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/16\">",
"      Kavanagh KT, Litovitz T. Miniature battery foreign bodies in auditory and nasal cavities. JAMA 1986; 255:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/17\">",
"      Premachandra DJ, McRae D. Severe tissue destruction in the ear caused by alkaline button batteries. Postgrad Med J 1990; 66:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/18\">",
"      Bhisitkul DM, Dunham M. An unsuspected alkaline battery foreign body presenting as malignant otitis externa. Pediatr Emerg Care 1992; 8:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/19\">",
"      Supiyaphun P, Sukumanpaiboon P. Acute otalgia: a case report of mature termite in the middle ear. Auris Nasus Larynx 2000; 27:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/20\">",
"      Leffler S, Cheney P, Tandberg D. Chemical immobilization and killing of intra-aural roaches: an in vitro comparative study. Ann Emerg Med 1993; 22:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/21\">",
"      Antonelli PJ, Ahmadi A, Prevatt A. Insecticidal activity of common reagents for insect foreign bodies of the ear. Laryngoscope 2001; 111:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/22\">",
"      Smith M, Darrat I, Seidman M. Otologic complications of cotton swab use: one institution's experience. Laryngoscope 2012; 122:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/23\">",
"      Talmi YP, Wolf M, Migirov L, Kronenberg J. Ear trauma caused by a yucca plant leaf spine. Ear Nose Throat J 2009; 88:E11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/24\">",
"      Singh GB, Sidhu TS, Sharma A, et al. Management of aural foreign body: an evaluative study in 738 consecutive cases. Am J Otolaryngol 2007; 28:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/25\">",
"      Schulze SL, Kerschner J, Beste D. Pediatric external auditory canal foreign bodies: a review of 698 cases. Otolaryngol Head Neck Surg 2002; 127:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/26\">",
"      Thompson SK, Wein RO, Dutcher PO. External auditory canal foreign body removal: management practices and outcomes. Laryngoscope 2003; 113:1912.",
"     </a>",
"    </li>",
"    <li>",
"     Marin JR, Trainor JL. Foreign body removal from the external auditory canal in a pediatric emergency department. Pediatr Emerg Care 2006; 22:630. (cross reference).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/28\">",
"      DiMuzio J Jr, Deschler DG. Emergency department management of foreign bodies of the external ear canal in children. Otol Neurotol 2002; 23:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/29\">",
"      Cederberg CA, Kerschner JE. Otomicroscope in the emergency department management of pediatric ear foreign bodies. Int J Pediatr Otorhinolaryngol 2009; 73:589.",
"     </a>",
"    </li>",
"    <li>",
"     Steele D. Foreign body removal from the external auditory canal. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM.  (Eds), Lippincott, Williams &amp; Willkins, Philadelphia 2008. p.589.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/31\">",
"      Dinsdale RC, Roland PS, Manning SC, Meyerhoff WL. Catastrophic otologic injury from oral jet irrigation of the external auditory canal. Laryngoscope 1991; 101:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/32\">",
"      Brown L, Denmark TK, Wittlake WA, et al. Procedural sedation use in the ED: management of pediatric ear and nose foreign bodies. Am J Emerg Med 2004; 22:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/33\">",
"      Isaacson G. Two-stage removal of an impacted foreign body with an epoxied anchor. Ann Otol Rhinol Laryngol 2003; 112:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/34\">",
"      McLaughlin R, Ullah R, Heylings D. Comparative prospective study of foreign body removal from external auditory canals of cadavers with right angle hook or cyanoacrylate glue. Emerg Med J 2002; 19:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/35\">",
"      Abadir WF, Nakhla V, Chong P. Removal of superglue from the external ear using acetone: case report and literature review. J Laryngol Otol 1995; 109:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/36\">",
"      Persaud R. A novel approach to the removal of superglue from the ear. J Laryngol Otol 2001; 115:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/37\">",
"      Balbani AP, Sanchez TG, Butugan O, et al. Ear and nose foreign body removal in children. Int J Pediatr Otorhinolaryngol 1998; 46:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28504/abstract/38\">",
"      Bressler K, Shelton C. Ear foreign-body removal: a review of 98 consecutive cases. Laryngoscope 1993; 103:367.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83464 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28504=[""].join("\n");
var outline_f27_53_28504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19482384\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H903746\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19482341\">",
"      FOREIGN BODIES OF THE PINNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H903865\">",
"      Relevant anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H903858\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H903851\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13832065\">",
"      Removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13832468\">",
"      Treatment of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19482771\">",
"      FOREIGN BODIES OF THE EXTERNAL AUDITORY CANAL (EAC)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19482348\">",
"      Relevant anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29168905\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8360855\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8360863\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19482355\">",
"      Removal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19482363\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19482370\">",
"      - Indications for consultation or referral to a specialist",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19482377\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1372265\">",
"      Irrigation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1372407\">",
"      Instrumentation under direct visualization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2249451\">",
"      Cyanoacrylate glue occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1372905\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19482384\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/83464\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/83464|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/57/8081\" title=\"figure 1\">",
"      Auricle anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/32/33285\" title=\"figure 2\">",
"      Normal ear anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/5/41043\" title=\"figure 3\">",
"      Weber and Rinne tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/56/11140\" title=\"figure 4\">",
"      Cerumen or ear foreign body removal by irrigation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/2/12323\" title=\"figure 5\">",
"      Removal of killed insect from the ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/28/14787\" title=\"figure 6\">",
"      Removal of foam rubber from the ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/42/42658\" title=\"figure 7\">",
"      Removal of round ear foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/6/4195\" title=\"figure 8\">",
"      Removal of spherical ear foreign body",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/83464|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/40/12929\" title=\"picture 1\">",
"      Embedded earring with infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/29/20947\" title=\"picture 2\">",
"      Cauliflower ear deformity from infected piercing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/48/29443\" title=\"picture 3\">",
"      Embedded earring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/40/29314\" title=\"picture 4\">",
"      Auricular perichondritis with abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/39/35440\" title=\"picture 5A\">",
"      Congenital cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/11/2226\" title=\"picture 5B\">",
"      Foreign bodies ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/8/20608\" title=\"picture 6\">",
"      Insect in the external auditory canal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/26/11682\" title=\"picture 7\">",
"      Penetrating ear foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/24/28032\" title=\"picture 8\">",
"      Papoose restraint for ear or nose foreign body removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/30/19940\" title=\"picture 9\">",
"      Equipment for removal of ear foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/31/36351\" title=\"picture 10\">",
"      Headlamp for ear foreign body removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/11/179\" title=\"picture 11\">",
"      Schuknecht foreign body remover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/83464|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/12/20684\" title=\"table 1\">",
"      Otorrhea causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/29/13787\" title=\"table 2\">",
"      Interpreting Weber and Rinne tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6137?source=related_link\">",
"      Assessment and management of auricle (ear) lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=related_link\">",
"      Evaluation and management of middle ear trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24728?source=related_link\">",
"      Evaluation of otorrhea (ear discharge) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/57/10130?source=related_link\">",
"      Patient information: Removing objects stuck in the ear (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_53_28505="Classification of unstable angina and non-ST elevation myocardial infarction";
var content_f27_53_28505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification of unstable angina and non-ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/53/28505/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28505/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/53/28505/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28505/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/53/28505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28505/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/53/28505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-ST elevation acute coronary syndromes (ACS) &mdash; unstable angina (UA) and non-ST elevation (non-Q wave) myocardial infarction (NSTEMI) &mdash; occur in a variety of clinical settings. The definitions of and classification systems for UA and NSTEMI and their use to assess risk will be reviewed here. Issues related to the evaluation, treatment, and risk stratification of patients with non-ST elevation ACS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both UA and NSTEMI, as well as ST elevation MI, are associated with unstable coronary lesions and plaque rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UA and NSTEMI differ primarily in whether the ischemia is severe enough to cause sufficient myocardial damage to release detectable quantities of a marker of myocardial injury. Unstable angina is considered to be present in patients with ischemic symptoms suggestive of an ACS and no elevation in troponin or CK-MB, with or without ECG changes indicative of ischemia (eg, ST segment depression or transient elevation or new T wave inversion). Since an elevation in troponin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CK-MB may not be detectable for up to 12 hours after presentation, UA and NSTEMI are frequently indistinguishable at initial evaluation. ST segment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T wave changes are often persistent in NSTEMI while, if they occur in UA, they are usually transient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2012 joint task force of the European Society of Cardiology (ESC), American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Health Federation (WHF) defined MI (in pathologic terms) as myocardial cell death due to prolonged ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The joint task force further refined the definition of MI by developing a clinical classification according to the assumed proximate cause of the myocardial ischemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 (Spontaneous): Spontaneous MI related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, of dissection with resulting intraluminal thrombus in one or more of the coronary arteries leading to decreased myocardial blood flow or distal platelet emboli with ensuing myocyte necrosis.",
"     </li>",
"     <li>",
"      Type 2 (Secondary to an ischemic imbalance): Instances of myocardial injury with necrosis where a condition other than coronary artery disease contributes to an imbalance between myocardial oxygen supply",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      demand, such as might occur with coronary endothelial dysfunction, coronary artery spasm, coronary embolism,",
"      <span class=\"nowrap\">",
"       tachy-/brady",
"      </span>",
"      arrhythmias, anemia, respiratory failure, hypotension, and hypertension with or without left ventricular hypertrophy.",
"     </li>",
"     <li>",
"      Type 3 (MI resulting in death when biomarker values are not available): Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic ECG changes or new LBBB, but death occurring before blood samples could be obtained, before cardiac biomarker could rise, or in rare cases cardiac biomarkers were not collected.",
"     </li>",
"     <li>",
"      Type 4a (PCI): Percutaneous coronary intervention related MI is defined by elevation of cardiac troponin (cTn) values &gt;5 x 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile upper reference limit (URL) in patients with normal baseline values (&le;99",
"      <sup>",
"       th",
"      </sup>",
"      percentile URL) or a rise of cTn &gt;20 percent if the baseline values are elevated and are stable or falling. In addition, either (1) symptoms suggestive of myocardial ischemia, or (2) new ischemic ECG changes or new LBBB, or (3) angiographic loss of patency of a major coronary artery or a side branch or persistent slow-or no-flow or embolization, or (4) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality are required.",
"     </li>",
"     <li>",
"      Type 4b (Stent thrombosis): MI associated with stent thrombosis is detected by coronary angiography or autopsy in the setting of myocardial ischemia and with a rise",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fall of cardiac biomarker values with at least one value above the 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile (URL).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Type 5 (CABG): MI associated with coronary artery bypass graft surgery is defined by elevation of cardiac biomarker values &lt; 10 x 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile URL in patients with normal cTn values (&le;99",
"    <sup>",
"     th",
"    </sup>",
"    percentile URL). In addition, either (1) new pathological Q waves or new LBBB, or (2) angiographic documented new graft or new native artery occlusion, or (3) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF UNSTABLE ANGINA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unstable angina can have a variety of different presentations which, as will be described in more detail below, may correlate with prognosis in the absence of intervention. Regardless of type, the risk is greatest with angina that is refractory to or occurs despite maximal medical therapy and with an accelerating tempo of ischemic symptoms in the preceding 48 hours (crescendo angina) (",
"    <a class=\"graphic graphic_table graphicRef55745 \" href=\"UTD.htm?6/60/7117\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Prognosis according to type'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     New onset angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of new onset angina depends in part upon the degree of exertion required to induce chest pain. Patients with new onset angina occurring only after heavy physical exertion have a prognosis similar to patients with chronic stable angina. In comparison, new angina occurring after minimal exercise or at rest, particularly if prolonged, carries a worse prognosis in the absence of intervention. In the original Braunwald classification of unstable angina, new onset was defined as less than two months in duration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rest angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rest angina, particularly if prolonged",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated with transient ST segment changes &gt;0.05 mV, identifies patients at increased risk (",
"    <a class=\"graphic graphic_table graphicRef55745 \" href=\"UTD.htm?6/60/7117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Early post-MI angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early postinfarction angina (defined as chest pain occurring within 48 hours after an acute MI) is typically associated with complex lesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent intracoronary thrombus and with more severe coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The recurrent chest pain may signify either remaining viable myocardium in the infarct zone or a different area of myocardium at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/5\">",
"     5",
"    </a>",
"    ]. In a report from the GISSI-3 trial, angina occurred at rest in 94 percent of patients; one-third of episodes occurred within 72 hours of the MI and between 6 and 10 AM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angina occurring soon after an acute MI is associated with high risk in the absence of intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/4,6-8\">",
"     4,6-8",
"    </a>",
"    ]. This was illustrated in a report from the GUSTO-IIb trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/7\">",
"     7",
"    </a>",
"    ]. Among 3513 patients with an NSTEMI (using the old definition that did not include serum troponins), 36 percent had recurrent ischemia that was responsive to medical therapy in 79 percent. Patients with recurrent ischemia that was refractory or responsive to medical therapy had a higher rate of reinfarction at 30 days (29 and 12 versus 3 percent in those without recurrent ischemia) and six months. In addition, the occurrence of refractory ischemia was associated with a higher mortality compared to responsive ischemia or no ischemia at 30 days (16 versus 6 and 4.3 percent) and one year. Similar findings were noted among 4125 patients with an STEMI and in over 40,000 patients with an STEMI in GUSTO-I [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GUSTO IIb also included 4488 patients with UA; 34 percent had recurrent ischemia that was responsive to medical therapy in 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients with recurrent ischemia that was refractory or responsive to medical therapy had a higher rate of reinfarction at 30 days (22 and 7.2 versus 2.3 for in without recurrent ischemia) and six months. In addition, the occurrence of refractory ischemia was associated with a higher 30 day mortality compared to responsive ischemia or no ischemia (8.2 versus 2.9 and 1.6 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Postrevascularization angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angina after percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) can reflect a procedural event or, over the long-term, restenosis after PCI (less with stenting compared to angioplasty alone, particularly with drug-eluting stents), stenosis in a graft (usually with saphenous vein grafts), or progression of native disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Periprocedural",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic chest pain within 48 hours after stenting usually results from procedural events such as abrupt vessel closure (usually due to stent thrombosis or progression of an untreated dissection), transient coronary spasm, side branch occlusion, or distal embolization of atherosclerotic or thrombotic debris. Some patients have asymptomatic enzyme elevations indicative of small infarctions. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'After PCI'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the EPISTENT trial, the incidence of ischemic chest pain was 11 percent, 12 percent of whom had associated ECG changes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/9\">",
"     9",
"    </a>",
"    ]. When ECG changes were present, there was a significantly increased risk (42 percent) of a cardiac event (death, all MI, repeat revascularization) compared to an intermediate risk of a cardiac event (13 percent) when chest pain without ECG changes was present, and the low risk (5 percent) in the absence of chest pain.",
"   </p>",
"   <p>",
"    An important diagnostic consideration soon after PCI is the distinction between ischemic and nonischemic chest pain. Nonischemic chest pain is typically manifested at rest, without ECG changes or elevation of cardiac enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Most patients describe pain characteristics different from their typical angina (more localized and frequently pleuritic). This discomfort lasts for less than 72 hours in about 80 percent of patients, and less than two weeks in the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/10\">",
"     10",
"    </a>",
"    ]. Overexpansion of the stent is thought to be responsible in most cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As after PCI, recurrent angina during the postoperative period after CABG is usually due to a technical problem with a graft or with early graft closure. It is therefore an indication for prompt catheterization with revascularization by PCI, if feasible. The diagnosis of recurrent ischemia may be difficult to make after CABG, since cardiac enzyme elevations occur as a result of the surgical procedure and since electrocardiographic changes may reflect postoperative pericardial inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Late",
"    </span>",
"    &nbsp;&mdash;&nbsp;The delayed onset of angina can reflect restenosis after PCI, graft stenosis after CABG, or progression of native disease. Affected patients typically present with the gradual and progressive return of effort angina. Prompt stress testing should be performed, since these patients are at increased risk. Stress radionuclide myocardial perfusion imaging or echocardiography is preferred over exercise ECG testing, since these modalities can document both the site and extent of ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20138?source=see_link\">",
"     \"Role of stress testing after coronary revascularization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While less common, some patients with recurrent ischemia present with UA. Such patients should be evaluated with cardiac catheterization after adequate medical stabilization.",
"   </p>",
"   <p>",
"    Unstable angina can also occur in patients with prior CABG; such patients have an increased rate of significant coronary events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This issue was best illustrated in the PURSUIT trial of almost 11,000 patients with a non-ST ACS, 12 percent (1134 patients) of whom had a prior CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients with a prior CABG had a significantly higher mortality at 30 days (5.2 versus 3.4 percent without a prior CABG, adjusted hazards ratio 1.45) and six months (8 versus 6.6 percent, adjusted hazards ratio 1.32). This difference may reflect a greater degree of cardiac disease.",
"   </p>",
"   <p>",
"    The older the saphenous vein graft, the higher the likelihood that UA is due to a culprit lesion within the graft (",
"    <a class=\"graphic graphic_figure graphicRef50106 \" href=\"UTD.htm?1/58/1966\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/14\">",
"     14",
"    </a>",
"    ]. Grafts are more likely than native vessels to show total occlusion or thrombus, complications that are more refractory to medical therapy. Among patients who undergo PCI for saphenous vein graft disease, the development of restenosis is manifested by an UA presentation in as many as 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=see_link\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Absence of significant coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In different clinical trials and the CRUSADE registry, 9 to 14 percent of patients with a non-ST elevation ACS have, on coronary angiography, either normal vessels or no vessel with &ge;50 to 60 percent stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/16-22\">",
"     16-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible mechanisms for the absence of marked coronary disease in these patients include coronary thrombosis with rapid clot lysis, vasospasm, macroemboli and microemboli, coagulopathy, vasculitis, small vessel disease, coronary microvascular dysfunction and myocarditis. In favor of the last mechanism is the observation in a report from the TIMI IIIA trial that approximately one-third of these patients had abnormally slow angiographic filling (TIMI flow grade 2 or less) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/17\">",
"     17",
"    </a>",
"    ]. The absence of significant coronary disease has also been described in patients with stable angina. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5802?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the TIMI IIIA trial of 391 patients with rest angina who did or did not receive fibrinolytic therapy, 53 (14 percent) fulfilled this criterion; one-half had no visually detectable coronary stenosis on angiography, and one-half had a noncritical coronary narrowing without findings suggestive of an unstable lesion such as ulceration or thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/17\">",
"     17",
"    </a>",
"    ]. When compared to patients with UA and a culprit coronary lesion on angiography, those with relatively normal coronary arteries were more likely to be women and to have no ST segment deviation.",
"   </p>",
"   <p>",
"    The characteristics of patients with UA who have mild or no coronary disease was further examined in a study of 5767 patients with a non-ST segment elevation ACS who were enrolled in the PURSUIT trial and who underwent angiography: 6 percent had mild coronary disease (&gt;0 to &le;50 percent stenosis) and 6 percent had no disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/18\">",
"     18",
"    </a>",
"    ]. The strongest independent predictors of insignificant coronary disease were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Younger age.",
"     </li>",
"     <li>",
"      Female sex; a greater prevalence of mild or no coronary disease in women was also noted in the TACTICS-TIMI 18 trial (17 versus 9 percent in men) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Absence of enrollment MI, prior angina, diabetes, or ST segment depression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar predictors of insignificant coronary disease, as well as lack of",
"    <span class=\"nowrap\">",
"     current/recent",
"    </span>",
"    smoking, were found in the CRUSADE registry [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possible role of cardiovascular magnetic resonance imaging in patients who present with chest pain, elevated troponin levels and absence of significant coronary artery disease on angiography is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with a non-ST elevation ACS who do not have significant coronary disease have a better outcome than those with a culprit coronary lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF NSTEMI",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, UA and NSTEMI are frequently indistinguishable at initial evaluation of patients who present with suspected ischemic chest pain, since an elevation in serum troponins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CK-MB are usually not detectable for four to six hours after an MI and at least 12 hours are required to detect elevations in all patients. Thus, the above discussion of the classification of UA also applies to patients with NSTEMI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     ST segment changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with NSTEMI present with chest pain and ST segment depression. ST segment depression is an adverse predictor in patients with a non-ST elevation ACS (",
"    <a class=\"graphic graphic_figure graphicRef57088 \" href=\"UTD.htm?15/44/16078\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67473 \" href=\"UTD.htm?30/55/31614\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. This is due in part to an increased incidence of left main or three vessel disease compared to those without ST segment depression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another subset of patients present with chest pain and initial ST segment elevation but no Q waves. These patients are treated for an ST elevation MI, but some never develop Q waves. Such patients have a better prognosis than those who develop Q waves because of more frequent reperfusion and a less severe infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H17#H17\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'Absence of Q waves after therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absence of Q waves in patients with an NSTEMI reflects a high rate of spontaneous reperfusion or presence of a tight stenosis without initial occlusion; 60 to 85 percent do not have occlusion of the culprit artery on arteriography performed soon after presentation. This presumably explains the lack of benefit from thrombolytic therapy in patients with an NSTEMI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     After PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSTEMI (Type 4a) can occur after percutaneous coronary intervention (PCI), a setting in which it is primarily manifested by an",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    elevation in serum biomarkers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/26-32\">",
"     26-32",
"    </a>",
"    ]. This problem is discussed in detail elsewhere but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported incidence of periprocedural NSTEMI has ranged from 5 to 30 percent and is higher with stenting than balloon angioplasty alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/26,30\">",
"     26,30",
"    </a>",
"    ]. Among patients receiving a stent, the incidence is increased with suboptimal stenting (eg, 8.7 versus 4.2 percent with optimal stenting in the STARS trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/27\">",
"     27",
"    </a>",
"    ], a shorter period of pretreatment with a thienopyridine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/28\">",
"     28",
"    </a>",
"    ], and a greater atherosclerotic burden [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac troponins are a more sensitive marker than CK-MB for minor degrees of myocardial damage, and elevated values after PCI with or without stenting may be more common than increases in serum CK-MB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. There is a graded relationship between the degree of enzyme elevation and increased six month mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is thought that the most common cause of elevated serum enzymes after PCI is distal embolization of friable plaque constituents and occlusion of minor side branches, rather than reduced epicardial blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. It has been suggested that patients with serum CK-MB more than three times the upper limit of normal or with ECG changes diagnostic of an STEMI should be treated as if they had an acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2012 joint task force of the European Society of Cardiology (ESC), American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Health Federation (WHF) defined acute MI after PCI as an elevation of cardiac troponin values &gt;5 x 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile in patients with normal baseline values (&le;99",
"    <sup>",
"     th",
"    </sup>",
"    percentile upper reference limit) or a rise of cardiac troponin values &gt;20 percentile if the baseline values are elevated and are stable or falling [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H107850186#H107850186\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'After revascularization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     After CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic accuracy of serum biomarkers is reduced after CABG due to their release as a routine sequela of the procedure. As an example, an increase in serum CK-MB above the upper limit of normal has been noted in 60 to 90 percent of patients. As a result, the diagnosis of NSTEMI or STEMI after CABG (type 5) usually requires characteristic ECG changes. However, patients with substantial elevations in serum markers (eg, serum CK-MB more than 10 times the upper limit of normal) are generally considered to have an MI and a worse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/35\">",
"     35",
"    </a>",
"    ]. The 2012 joint task force of the European Society of Cardiology (ESC), American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Health Federation (WHF) defined acute MI after CABG as an elevation of cardiac biomarker values &gt;10 x 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile upper reference limit in patients with normal baseline cardiac troponin values (&le;99",
"    <sup>",
"     th",
"    </sup>",
"    percentile upper reference limit) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H107850186#H107850186\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'After revascularization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS ACCORDING TO TYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different types of non-ST elevation ACS are associated with different risks of adverse outcomes. This observation led to attempts to risk stratify such patients. However, as will be described below, these efforts have limited applicability to current practice since almost all high or intermediate risk patients and many low risk patients now undergo coronary revascularization if available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Original Braunwald classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;A classification of UA was proposed by Braunwald in 1989 to facilitate the assignment of patients to a particular risk group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/2\">",
"     2",
"    </a>",
"    ]. This classification, which included patients with NSTEMI since troponins were not measured, takes into account the severity of symptoms, the clinical circumstances surrounding the anginal episode, and the intensity of treatment (",
"    <a class=\"graphic graphic_table graphicRef74808 \" href=\"UTD.htm?21/46/22251\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Severity",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Class I &mdash; New onset, severe, or accelerated",
"     </li>",
"     <li>",
"      Class II &mdash; Angina at rest and subacute (no anginal episodes within the preceding 48 hours)",
"     </li>",
"     <li>",
"      Class III &mdash; Angina at rest and acute (angina within the preceding 48 hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical circumstances",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Class A &mdash; Secondary UA (in the setting of anemia, infection, fever, etc)",
"     </li>",
"     <li>",
"      Class B &mdash; Primary UA",
"     </li>",
"     <li>",
"      Class C &mdash; Post-MI angina",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intensity of treatment",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No or minimal treatment",
"     </li>",
"     <li>",
"      Symptoms occurring in the setting of standard medical therapy",
"     </li>",
"     <li>",
"      Symptoms occurring despite maximally tolerated doses of beta blockers, nitrates, and calcium channel blockers",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Correlation with angiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease severity predicted by the original classification correlated with angiographic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. As an example, angiographic correlates were evaluated in 238 consecutive patients admitted with the diagnosis of UA to a large tertiary care hospital: 2 percent had secondary angina (class A), 60 percent had primary angina (class B), and 38 percent had post-MI angina (class C) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/36\">",
"     36",
"    </a>",
"    ]. Multivariate regression analysis identified an angina score (assigned on the basis of one point for class I and class A, two points for class II and class B, and three points for class III and class C) as the most important predictor of angiographically demonstrable intracoronary thrombus and lesion complexity in the ischemia-related artery (",
"    <a class=\"graphic graphic_figure graphicRef75109 \" href=\"UTD.htm?20/48/21262\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In another report, patients with class III angina (rest angina within 48 hours) were more likely to have complex lesions (eccentric, ulcerated, irregular borders, or overhanging edges, associated with an intracoronary filling defect) and decreased Thrombolysis in Myocardial Infarction (TIMI) grade flow [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients with class C angina (post-infarction angina) were more likely to have complex lesions, reduced TIMI flow, and intracoronary thrombus. Class C angina (refractory to medical therapy) was also correlated with intracoronary thrombus.",
"   </p>",
"   <p>",
"    Despite these general correlations between clinical presentation and angiography, approximately 12 to 14 percent of patients with a non-ST elevation ACS do not have significant coronary disease at angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Absence of significant coronary disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Prediction of outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective study of 417 patients attempted to identify the incidence and prognosis of different classification groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/39\">",
"     39",
"    </a>",
"    ]. After hospital admission, recurrence of chest pain increased with higher severity class (28, 45, and 64 percent for classes I, II, and III) but was the same in different clinical circumstances classes (49, 53, and 53 percent for classes A, B, and C). Six month infarct-free and patient survival were significantly lower for class C than for classes A and B (89 versus 97 percent and 80 versus 89 percent, respectively). In addition to class C, other independent predictors of death were older age, male sex, hypertension, and maximal medical therapy.",
"   </p>",
"   <p>",
"    Similar findings were noted in a community-based series of 393 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/40\">",
"     40",
"    </a>",
"    ]. Two other clinical factors, older age and diabetes, were also predictors of adverse outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Limitations and adjustments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original Braunwald classification had a number of weaknesses including substantial overlap between the groups and difficulty in identifying very low risk patients. In addition, a number of important clinical considerations were not included, such as age, gender, the physical examination, the presence or absence of electrocardiographic (ECG) changes, the presence of comorbid illness known to increase the risk of coronary disease such as diabetes or peripheral artery disease, and the prognostic importance of serum troponins which, according to the definition of myocardial infarction, identifies patients with an NSTEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The 2007 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines on the management of non-ST elevation ACS proposed criteria for the identification of high-, intermediate-, and low-risk patient groups for both significant coronary artery disease (",
"    <a class=\"graphic graphic_table graphicRef69999 \" href=\"UTD.htm?32/11/32956\">",
"     table 3",
"    </a>",
"    ) and short-term risk of death or nonfatal myocardial infarction (",
"    <a class=\"graphic graphic_table graphicRef55745 \" href=\"UTD.htm?6/60/7117\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic importance of serum troponins and ST segment depression was demonstrated in a report in which patients with UA class IIIB were subdivided into troponin positive and troponin negative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/23\">",
"     23",
"    </a>",
"    ]. The patients who were troponin-positive (who would now be considered to have an NSTEMI) had a much higher risk of cardiac death or MI at 30 days (15 to 20 versus less than 2 percent) (",
"    <a class=\"graphic graphic_figure graphicRef57088 \" href=\"UTD.htm?15/44/16078\">",
"     figure 2",
"    </a>",
"    ). ST segment depression also had independent adverse predictive value. The adverse outcome in troponin-positive patients could be related to a greater likelihood of complex lesion characteristics and visible thrombus at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although angiographic features were not included in any of these risk classifications, the subset of patients (12 to 14 percent) without significant coronary disease is at much lower short-term risk than those with a culprit lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Absence of significant coronary disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Applicability to current practice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original and amended Braunwald classifications and the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines remain valuable during the assessment of patients with a non-ST elevation ACS. However, their predictive value for outcome is limited since almost all high or intermediate risk patients and many low risk patients now undergo coronary revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The TIMI risk score is the most widely used and validated predictive instrument in patients with a non-ST elevation ACS (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/24\">",
"     24",
"    </a>",
"    ]. In the TACTICS-TIMI 18 trial, for example, only patients at moderate to high risk (score &ge;3) benefited from an early invasive strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28505/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'TIMI risk score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       \"Patient information: Heart attack (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unstable angina (UA) and non-ST elevation myocardial infarction (NSTEMI), along with ST elevation myocardial infarction (STEMI), are the three types of acute coronary syndromes (ACS). UA and NSTEMI differ primarily in whether the ischemia is severe enough to cause sufficient myocardial damage to release detectable quantities of a marker of myocardial injury.",
"   </p>",
"   <p>",
"    Unstable angina is present in patients with symptoms suggestive of an ACS but no elevation biomarkers. Electrocardiographic (ECG) changes indicative of ischemia (eg, ST segment depression or transient elevation or new T wave inversion) may or may not be present. Since an elevation in biomarkers may not be detectable for up to 12 hours after presentation, UA and NSTEMI are frequently indistinguishable at initial evaluation. ST segment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T wave changes are often persistent in NSTEMI while, if they occur in UA, they are usually transient. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Classification of unstable angina'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Unstable angina is further categorized based upon patient characteristics at the time of presentation. New onset, rest, early post-MI, and post revascularization angina are examples. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Classification of unstable angina'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients in whom NSTEMI is ultimately diagnosed by an elevation of biomarker, a detailed classification scheme (which also applies to STEMI) was developed by the 2012 joint task force of the European Society of Cardiology, American College of Cardiology Foundation, the American Heart Association and the World Health Federation. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with NSTEMI, the ECG on presentation may show no gross abnormalities, ST elevation or depression, or T wave inversion. Q waves on the ECG may or may not develop in those with no abnormalities, ST depression, or T wave inversion. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Classification of NSTEMI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The different types of non-ST elevation ACS are associated with different risks of adverse outcomes. However, these efforts have limited applicability to current practice since almost all high or intermediate risk patients and many low risk patients now undergo coronary revascularization. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Prognosis according to type'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/1\">",
"      Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012; 126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/2\">",
"      Braunwald E. Unstable angina. A classification. Circulation 1989; 80:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/3\">",
"      Patel DJ, Gomma AH, Knight CJ, et al. Why is recurrent myocardial ischaemia a predictor of adverse outcome in unstable angina? An observational study of myocardial ischaemia and its relation to coronary anatomy. Eur Heart J 2001; 22:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/4\">",
"      Bosch X, Th&eacute;roux P, Waters DD, et al. Early postinfarction ischemia: clinical, angiographic, and prognostic significance. Circulation 1987; 75:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/5\">",
"      Schuster EH, Bulkley BH. Early post-infarction angina. Ischemia at a distance and ischemia in the infarct zone. N Engl J Med 1981; 305:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/6\">",
"      Early and six-month outcome in patients with angina pectoris early after acute myocardial infarction (the GISSI-3 APPI [angina precoce post-infarto] study). The GISSI-3 APPI Study Group. Am J Cardiol 1996; 78:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/7\">",
"      Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/8\">",
"      Betriu A, Califf RM, Bosch X, et al. Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 31:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/9\">",
"      Robbins MA, Marso SP, Wolski K, et al. Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])]. Am J Cardiol 1999; 84:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/10\">",
"      Kini AS, Lee P, Mitre CA, et al. Postprocedure chest pain after coronary stenting: implications on clinical restenosis. J Am Coll Cardiol 2003; 41:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/11\">",
"      Jeremias A, Kutscher S, Haude M, et al. Nonischemic chest pain induced by coronary interventions: a prospective study comparing coronary angioplasty and stent implantation. Circulation 1998; 98:2656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/12\">",
"      Labinaz M, Kilaru R, Pieper K, et al. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2002; 105:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/13\">",
"      Kleiman NS, Anderson HV, Rogers WJ, et al. Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry). Am J Cardiol 1996; 77:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/14\">",
"      Chen L, Th&eacute;roux P, Lesp&eacute;rance J, et al. Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery. J Am Coll Cardiol 1996; 28:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/15\">",
"      Chandrasekar B, Bourassa MG. Incidence and risk factors predictive of unstable angina resulting from restenosis after percutaneous angioplasty of saphenous vein grafts. Am Heart J 2000; 140:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/16\">",
"      Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med 2006; 166:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/17\">",
"      Diver DJ, Bier JD, Ferreira PE, et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardiol 1994; 74:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/18\">",
"      Roe MT, Harrington RA, Prosper DM, et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation 2000; 102:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/19\">",
"      Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/20\">",
"      Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/21\">",
"      Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 2002; 288:3124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/22\">",
"      Patel MR, Chen AY, Peterson ED, et al. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. Am Heart J 2006; 152:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/23\">",
"      Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation 2000; 102:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/24\">",
"      Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/25\">",
"      Diderholm E, Andr&eacute;n B, Frostfeldt G, et al. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J 2002; 143:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/26\">",
"      Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/27\">",
"      Cutlip DE, Leon MB, Ho KK, et al. Acute and nine-month clinical outcomes after \"suboptimal\" coronary stenting: results from the STent Anti-thrombotic Regimen Study (STARS) registry. J Am Coll Cardiol 1999; 34:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/28\">",
"      Steinhubl SR, Lauer MS, Mukherjee DP, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol 1998; 32:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/29\">",
"      Mehran R, Dangas G, Mintz GS, et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions : intravascular ultrasound study of 2256 patients. Circulation 2000; 101:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/30\">",
"      Shyu KG, Kuan PL, Cheng JJ, Hung CR. Cardiac troponin T, creatine kinase, and its isoform release after successful percutaneous transluminal coronary angioplasty with or without stenting. Am Heart J 1998; 135:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/31\">",
"      Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 2000; 85:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/32\">",
"      Akkerhuis KM, Alexander JH, Tardiff BE, et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002; 105:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/33\">",
"      Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001; 103:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/34\">",
"      Gibson CM, Murphy SA, Marble SJ, et al. Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. Am Heart J 2002; 143:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/35\">",
"      Brener SJ, Lytle BW, Schneider JP, et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002; 40:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/36\">",
"      Ahmed WH, Bittl JA, Braunwald E. Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. Am J Cardiol 1993; 72:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/37\">",
"      De Servi S, Arbustini E, Marsico F, et al. Correlation between clinical and morphologic findings in unstable angina. Am J Cardiol 1996; 77:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/38\">",
"      Dangas G, Mehran R, Wallenstein S, et al. Correlation of angiographic morphology and clinical presentation in unstable angina. J Am Coll Cardiol 1997; 29:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/39\">",
"      van Miltenburg-van Zijl AJ, Simoons ML, Veerhoek RJ, Bossuyt PM. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris. J Am Coll Cardiol 1995; 25:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/40\">",
"      Calvin JE, Klein LW, VandenBerg BJ, et al. Risk stratification in unstable angina. Prospective validation of the Braunwald classification. JAMA 1995; 273:136.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28505/abstract/42\">",
"      Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 1999; 100:1509.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 43 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28505=[""].join("\n");
var outline_f27_53_28505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION OF UNSTABLE ANGINA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      New onset angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rest angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Early post-MI angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Postrevascularization angina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Periprocedural",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Late",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Absence of significant coronary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLASSIFICATION OF NSTEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ST segment changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      After PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      After CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS ACCORDING TO TYPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Original Braunwald classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Correlation with angiographic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Prediction of outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Limitations and adjustments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Applicability to current practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/43\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/43|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/58/1966\" title=\"figure 1\">",
"      Culprit lesion after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/44/16078\" title=\"figure 2\">",
"      Troponin predicts outcome in unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/55/31614\" title=\"figure 3\">",
"      TIMI risk score for non-ST elevation ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/48/21262\" title=\"figure 4\">",
"      Lesion complexity in UA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/43|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/60/7117\" title=\"table 1\">",
"      Risk of death or MI in UA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/46/22251\" title=\"table 2\">",
"      Classification unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/11/32956\" title=\"table 3\">",
"      Risk of significant CHD in UA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=related_link\" title=\"calculator 1\">",
"      Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5802?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=related_link\">",
"      Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20138?source=related_link\">",
"      Role of stress testing after coronary revascularization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_53_28506="Diagnostic approach to and treatment of thyroid nodules";
var content_f27_53_28506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to and treatment of thyroid nodules",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/53/28506/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28506/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/53/28506/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28506/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/53/28506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/53/28506/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/53/28506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid nodules come to clinical attention when noted by the patient, or as an incidental finding during routine physical examination, or during a radiologic procedure, such as carotid ultrasonography, neck computed tomography (CT), or positron emission tomography (PET) scanning. Several different disorders can cause thyroid nodules (",
"    <a class=\"graphic graphic_table graphicRef57701 \" href=\"UTD.htm?8/25/8604\">",
"     table 1",
"    </a>",
"    ). Their clinical importance is primarily related to the need to exclude thyroid cancer, which accounts for 4.0 to 6.5 percent of all thyroid nodules in non-surgical series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of cancer is higher in several groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Children",
"     </li>",
"     <li>",
"      Adults less than 30 years or over 60 years old",
"     </li>",
"     <li>",
"      Patients with a history of head and neck irradiation",
"     </li>",
"     <li>",
"      Patients with a family history of thyroid cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, the prevalence of cancer may be lower in nodules within multinodular goiters, and virtually all autonomously hyperfunctioning (\"hot\") nodules are benign. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1990?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of thyroid nodule formation\", section on 'Multinodular goiters'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic evaluation and treatment of thyroid nodules will be reviewed here. Fine needle aspiration techniques and common cytopathologic findings are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28056?source=see_link\">",
"     \"Thyroid biopsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24452?source=see_link\">",
"     \"Atlas of thyroid cytopathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical importance of the thyroid nodule evaluation is primarily related to the need to exclude thyroid cancer, which is present in 4.0 to 6.5 percent of thyroid nodules. Nonpalpable nodules (incidentalomas) have the same risk of malignancy as palpable nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Thus, the initial evaluation in all patients with a thyroid nodule (discovered either by palpation or incidentally noted on a radiologic procedure, such as carotid ultrasonography, neck CT, MRI, or PET) includes a history, physical examination, and measurement of serum thyroid stimulating hormone (TSH). Ultrasound is also recommended for all patients to confirm the presence of nodularity, assess sonographic features, and to assess for the presence of additional nodules and lymphadenopathy.",
"   </p>",
"   <p>",
"    Fine needle aspiration (FNA) biopsy is the most accurate method for evaluating thyroid nodules and identifying patients who require surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/9\">",
"     9",
"    </a>",
"    ]. If a serum TSH is normal or elevated, the next step in the evaluation of a thyroid nodule is a palpation or ultrasound-guided fine needle aspiration biopsy. If the nodule is complex or posterior, ultrasound guidance is strongly recommended to avoid nondiagnostic or incorrect cytology results. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Fine needle aspiration biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Over the last decade, the use of thyroid scintigraphy to assess thyroid nodules has become less common. Although scintigraphy remains the only way to determine the functional status of a nodule, high-resolution thyroid ultrasonography provides anatomic definition superior to thyroid scintigraphy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\"",
"    </a>",
"    .) Scintigraphy is useful in patients with a low serum TSH concentration. It may be useful in patients with multiple thyroid nodules to select those that are hypofunctional and therefore may require FNA.",
"   </p>",
"   <p>",
"    The figure summarizes our recommended evaluation of patients with thyroid nodules, beginning with TSH (",
"    <a class=\"graphic graphic_algorithm graphicRef75103 \" href=\"UTD.htm?3/27/3504\">",
"     algorithm 1",
"    </a>",
"    ). It is consistent with the American Thyroid Association guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination have a low accuracy for predicting cancer. However, there are several features of the clinical evaluation that suggest an increased likelihood of malignancy, such as a history of rapid growth of a neck mass, childhood head and neck irradiation, total body irradiation for bone marrow transplantation, family history of thyroid cancer, or thyroid cancer syndromes (eg, multiple endocrine neoplasia 2, familial adenomatous polyposis, or Cowden syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A fixed hard mass, obstructive symptoms, cervical lymphadenopathy, or vocal cord paralysis all suggest the possibility of cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serum TSH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid function should be assessed in all patients with thyroid nodules.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum TSH concentration is low, indicating overt or subclinical hyperthyroidism, the possibility that the nodule is hyperfunctioning is increased and thyroid scintigraphy should be performed next. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Thyroid scintigraphy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If the serum TSH concentration is normal or elevated, and the nodule meets criteria for sampling, then fine needle aspiration biopsy is indicated. In addition, patients with a high serum TSH concentration require an evaluation for hypothyroidism. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Indications'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"       \"Disorders that cause hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum TSH is an independent risk factor for predicting malignancy in a thyroid nodule. In a study of 1500 patients presenting to a thyroid practice, the prevalence of malignancy was 2.8, 3.7, 8.3, 12.3, and 29.7 percent for patients with serum TSH concentrations &lt;0.4",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    0.4 to 0.9",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    1.0 to 1.7",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    1.8 to 5.5",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    and &gt;5.5",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/11\">",
"     11",
"    </a>",
"    ]. A similar study demonstrated that when cancer was diagnosed, a higher TSH was associated with a more advanced stage of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thyroid ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid ultrasound should be performed in all patients with a suspected thyroid nodule or nodular goiter on physical examination or with nodules incidentally noted on other imaging studies (carotid ultrasound, CT, MRI, or FDG-PET scan).",
"   </p>",
"   <p>",
"    Thyroid ultrasonography is used to answer questions about the size and anatomy of the thyroid gland and adjacent structures in the neck. It provides considerably more anatomic detail than thyroid scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/13\">",
"     13",
"    </a>",
"    ], CT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/14\">",
"     14",
"    </a>",
"    ], and physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In a retrospective study of 173 patients referred to a thyroid nodule clinic for an abnormal thyroid examination, the ultrasound findings were different from the physical examination done by the referring clinician in 63 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/16\">",
"     16",
"    </a>",
"    ]. Of the 114 patients referred for a solitary nodule, 24 percent had additional nodules and 20 percent did not have a nodule of at least 1.0 cm that required aspiration. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are several ultrasonographic findings that are suspicious for thyroid cancer (",
"    <a class=\"graphic graphic_table graphicRef68199 \" href=\"UTD.htm?20/17/20763\">",
"     table 2",
"    </a>",
"    ). The predictive value of these characteristics varies widely, and we do not rely on thyroid ultrasound to diagnose cancer or to select patients for surgery. However, ultrasound findings can be used to select nodules for FNA biopsy. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Fine needle aspiration biopsy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\", section on 'Criteria for identifying cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasound can identify posteriorly located nodules or predominantly cystic nodules. The diagnostic accuracy of FNA performed by palpation is reduced in these nodules, and ultrasound-guided FNA is more effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31814?source=see_link&amp;anchor=H27370272#H27370272\">",
"     \"Ultrasound-guided thyroid biopsy\", section on 'Indications for ultrasound-guided FNA'",
"    </a>",
"    .) Apparent nodularity in Hashimoto's thyroiditis may represent focal enlargement from lymphocytic infiltrates, TSH-induced hyperplasia of follicular tissue, or a thyroid tumor. Ultrasonography may also help to distinguish among these possibilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Thyroid scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid scintigraphy is used to determine the functional status of a nodule. A low serum TSH, indicating overt or subclinical hyperthyroidism, increases the possibility that a thyroid nodule is hyperfunctioning. Thus, thyroid scintigraphy should be performed in patients with a low serum TSH concentration.",
"   </p>",
"   <p>",
"    Thyroid scintigraphy can be used to select nodules for FNA. It cannot be used to select patients for surgical resection.",
"   </p>",
"   <p>",
"    Scintigraphy utilizes one of the radioisotopes of iodine (usually 123I) or technetium-99m pertechnetate. If available, radioiodine scanning is preferred. These radioisotopes are handled differently by thyroid follicular cells. Normal thyroid follicular cells take up both technetium and radioiodine, but only radioiodine is organified and stored (as thyroglobulin) in the lumen of thyroid follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/17\">",
"     17",
"    </a>",
"    ]. Most benign and virtually all malignant thyroid nodules concentrate both radioisotopes less avidly than adjacent normal thyroid tissue (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68835 \" href=\"UTD.htm?5/18/5409\">",
"     image 1",
"    </a>",
"    ). However, 5 percent of thyroid cancers concentrate pertechnetate, but not radioiodine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/17\">",
"     17",
"    </a>",
"    ]. These nodules may appear hot or indeterminate (\"warm\") on pertechnetate scans and cold on radioiodine scans. Although most are benign nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], a few are thyroid cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. As a result, patients with nodules that are functioning on pertechnetate imaging should undergo radioiodine imaging to confirm that they are actually functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/19,23\">",
"     19,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nonfunctioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonfunctioning nodules appear cold (uptake less than surrounding thyroid tissue) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68835 \" href=\"UTD.htm?5/18/5409\">",
"     image 1",
"    </a>",
"    ), and they may require further evaluation by FNA. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Autonomous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomous nodules may appear hot (uptake is greater than surrounding thyroid tissue) (",
"    <a class=\"graphic graphic_picture graphicRef79487 \" href=\"UTD.htm?4/34/4655\">",
"     picture 1",
"    </a>",
"    ) if they are hyperfunctioning. Autonomous nodules that do not make sufficient thyroid hormone to suppress serum TSH concentrations will appear indeterminate on thyroid scintigraphy (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Indeterminate'",
"    </a>",
"    below). Autonomous nodules account for only 5 to 10 percent of palpable nodules. Only a few patients with autonomous nodules have been found to have thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], and only a few of these cancers were aggressive [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/27\">",
"     27",
"    </a>",
"    ]. Furthermore, in some of these patients, the cancer was adjacent to the autonomous nodule rather than within it. Since hyperfunctioning nodules rarely are cancer, a nodule that is hyperfunctioning on radioiodine imaging does not require FNA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Indeterminate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because scintigraphy is two-dimensional, its limitations result from the superimposition of abnormal nodular tissue and normally functioning thyroid tissue (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72057 \" href=\"UTD.htm?40/16/41216\">",
"     image 2",
"    </a>",
"    ). Thus, while over 80 percent of nonautonomous nodules greater than 2 cm appear cold, smaller nodules present as a filling defect in less than one-third of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/24\">",
"     24",
"    </a>",
"    ]. The remaining majority of smaller nodules are indeterminate on thyroid scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/28\">",
"     28",
"    </a>",
"    ]. They could represent either small non-functioning nodules anterior or posterior to normally functioning thyroid tissue, or autonomous nodules that do not produce sufficient thyroid hormone to suppress TSH (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51029 \" href=\"UTD.htm?14/33/14879\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These indeterminate nodules should",
"    <strong>",
"     not",
"    </strong>",
"    be referred to as warm or functioning since the majority are in fact non-functioning nodules. Most indeterminate nodules should be evaluated by FNA. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Fine needle aspiration biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The nature of an indeterminate nodule can be assessed by suppression scanning. This test is most commonly indicated in patients who have an indeterminate nodule and an FNA that was interpreted as a follicular neoplasm (microfollicular), or a follicular lesion of uncertain malignant potential, since these cytologic findings may be associated with autonomous nodules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24452?source=see_link&amp;anchor=H3#H3\">",
"     \"Atlas of thyroid cytopathology\", section on 'Follicular neoplasm/microfollicular cytology'",
"    </a>",
"    .) Rarely, this test may be indicated in a patient with an indeterminate nodule who refuses FNA. Patients with autonomously functioning nodules may become hyperthyroid with even small doses of T4 and should be warned of hyperthyroid symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/29\">",
"     29",
"    </a>",
"    ]. Therefore, this test should not be done in older patients or in those with angina or cardiac arrhythmias.",
"   </p>",
"   <p>",
"    Patients are given thyroid hormone in a dose sufficient to suppress TSH secretion, and a second scan is done once TSH suppression is documented, which may occur in one to two weeks or may require several dose adjustments. Suppression can usually be accomplished by administering T4 (2",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    for 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/30\">",
"     30",
"    </a>",
"    ]. Uptake of radioiodine will be low or undetectable in nonautonomous tissue, but persist in autonomous tissue (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67109 \" href=\"UTD.htm?27/62/28655\">",
"     image 4",
"    </a>",
"    ). If the region of nonsuppressible uptake corresponds to the palpable nodule, then the nodule can be assumed to be autonomous and benign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fine needle aspiration biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Thyroid Association recommends FNA biopsy as the procedure of choice for evaluating thyroid nodules and selecting candidates for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/10\">",
"     10",
"    </a>",
"    ]. FNA biopsy has resulted in improved diagnostic accuracy, a higher malignancy yield at the time of surgery, and significant cost reductions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/9,31,32\">",
"     9,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tissue for histologic or cytologic examination may be obtained from the thyroid by several different techniques, including cutting needle biopsy, large- or fine needle aspiration (FNA), or fine needle capillary sampling. FNA biopsy is the most commonly used approach. A complete discussion of the techniques, their value and limitations, and potential complications can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28056?source=see_link\">",
"     \"Thyroid biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FNA is a simple and safe office procedure in which tissue samples are obtained for cytologic examination using 23 to 27 gauge (commonly 25 gauge) needles with or without local anesthesia. With experience, adequate samples can be obtained in 90 to 97 percent of aspirations of solid nodules.",
"   </p>",
"   <p>",
"    Nonpalpable nodules (discovered incidentally during other imaging procedures) have the same risk of malignancy as palpable nodules of similar size [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Ultrasound-guided FNA biopsy can be performed for nonpalpable nodules and for nodules that are technically difficult to aspirate using palpation methods alone, such as predominantly cystic or posteriorly located nodules. In patients with large nodules (&gt;4 cm), ultrasound-guided FNA directed at several areas within the nodule may reduce the risk of a false negative biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31814?source=see_link&amp;anchor=H27370272#H27370272\">",
"     \"Ultrasound-guided thyroid biopsy\", section on 'Indications for ultrasound-guided FNA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37111?source=see_link\">",
"     \"Cystic thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that the presence of suspicious ultrasound features is more predictive of malignancy than nodule size alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/7,33\">",
"     7,33",
"    </a>",
"    ]. A decision analysis of thyroid nodule biopsy criteria for nodules measuring 1.0 to 1.5 cm favors the approach of selecting nodules with suspicious ultrasonographic characteristics for biopsy over the approach of biopsy for all nodules &ge;1 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/34\">",
"     34",
"    </a>",
"    ]. The American Thyroid Association has taken such an approach, and our approach is consistent with ATA guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients without risk factors for thyroid cancer, we perform FNA biopsy for solid hypoechoic nodules (palpable or nonpalpable) measuring &gt;1 cm. This recommendation is based upon observational studies that show similar rates of cancer in nonpalpable nodules &gt;1 cm and palpable nodules of similar size [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. FNA is also recommended for solid nodules that are isoechoic or hyperechoic, if they are &ge;1.0 to 1.5 cm, and for mixed cystic-solid nodules without suspicious features on ultrasound, if they are &ge;2.0 cm (",
"    <a class=\"graphic graphic_table graphicRef70513 \" href=\"UTD.htm?2/6/2157\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/10\">",
"     10",
"    </a>",
"    ]. Spongiform nodules, defined as an aggregation of multiple microcystic components in more than 50 percent of the nodule volume, may not require FNA regardless of size, although it may be prudent to biopsy spongiform nodules &gt;2.0 cm. Purely cystic nodules (no mural component) do not require a biopsy.",
"   </p>",
"   <p>",
"    In patients with risk factors for thyroid cancer (eg, childhood head and neck irradiation, family history of thyroid cancer), the ATA guidelines suggest that the nodule threshold size for FNA biopsy is smaller. The ATA guidelines recommend ultrasound-guided FNA biopsy for all nodules &gt;5 mm in high-risk patients (",
"    <a class=\"graphic graphic_table graphicRef70513 \" href=\"UTD.htm?2/6/2157\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/10\">",
"     10",
"    </a>",
"    ]. There are no data to support such an approach, and we prefer to biopsy subcentimeter nodules in both high and low risk patients, only if they have highly suspicious characteristics on ultrasound (",
"    <a class=\"graphic graphic_table graphicRef68199 \" href=\"UTD.htm?20/17/20763\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\", section on 'Criteria for identifying cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary studies suggest the potential use of an imaging staging system similar to that used for breast imaging. The TIRADS system rates ultrasound findings on a score of 1 to 5 based upon ultrasonographic characteristics; malignancy was found in 0 percent of category 2, 3.4 percent of category 3, 14 percent of category 4, and 86.5 percent of category 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/35\">",
"     35",
"    </a>",
"    ]. Studies are needed to assess the costs associated with the routine use of ultrasound to detect nonpalpable thyroid cancers, and the clinical impact of early detection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Multiple nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple nodules have the same risk of malignancy as those with a single nodule [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/16,33\">",
"     16,33",
"    </a>",
"    ]. Thus, the sonographic features of each nodule should be assessed independently to determine the need for FNA biopsy. If there are multiple coalescent nodules and none have suspicious sonographic features, FNA biopsy of the largest nodule is reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/10\">",
"     10",
"    </a>",
"    ]. The nodules that are not biopsied should be monitored with periodic ultrasonography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Monitoring of small nodules that are not biopsied",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients without risk factors for thyroid cancer or suspicious ultrasound findings, routine FNA is not recommended for nodules &lt;1 cm. We perform periodic ultrasonography (initially at 6 to 12 months, then at increasing intervals over time assuming stability, eg, at one to two year intervals, then three to five years) to evaluate for growth. If the nodule grows to &ge;1 to 2 cm and demonstrates the ultrasound characteristics discussed above, ultrasound-guided FNA should be performed.",
"   </p>",
"   <p>",
"    Indirect evidence for an observational approach to subcentimeter nonpalpable nodules comes from a Japanese study of 162 patients with small papillary cancers diagnosed by ultrasound-guided needle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/36\">",
"     36",
"    </a>",
"    ]. The average nodule size was 6.9 mm. The patients were among a group of 732 patients with positive biopsies; the remaining 570 patients chose surgery. During follow-up (half the patients were followed three to four years, 35 percent later opted for surgery), 70 percent were stable or were reduced in size, 1.2 percent developed lymph node metastases, and no one developed distant metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Diagnostic categories",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference (&ldquo;Bethesda Conference&rdquo;) suggests the following classification scheme [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign &mdash; this includes macrofollicular or",
"      <span class=\"nowrap\">",
"       adenomatoid/hyperplastic",
"      </span>",
"      nodules, colloid adenomas, nodular goiter, and Hashimoto's thyroiditis",
"     </li>",
"     <li>",
"      Follicular lesion or atypia of undetermined significance &mdash; this includes lesions with atypical cells, or mixed macro- and microfollicular nodules",
"     </li>",
"     <li>",
"      Follicular neoplasm &mdash; this includes microfollicular nodules, including H&uuml;rthle cell lesions",
"     </li>",
"     <li>",
"      Suspicious for malignancy",
"     </li>",
"     <li>",
"      Malignant",
"     </li>",
"     <li>",
"      Nondiagnostic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The terms used by different cytopathologists to describe follicular thyroid nodules vary (",
"    <a class=\"graphic graphic_table graphicRef70424 \" href=\"UTD.htm?4/60/5068\">",
"     table 4",
"    </a>",
"    ). It is essential that clinicians interpreting these reports be familiar with the terminology used by their cytopathologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24452?source=see_link\">",
"     \"Atlas of thyroid cytopathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28056?source=see_link&amp;anchor=H11#H11\">",
"     \"Thyroid biopsy\", section on 'Diagnostic categories'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450947\">",
"    <span class=\"h3\">",
"     Molecular markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;When cytologic results show follicular",
"    <span class=\"nowrap\">",
"     lesion/atypia",
"    </span>",
"    of undetermined significance or follicular neoplasm, the results are often called indeterminate. The risk of malignancy with these cytologic classifications ranges from 5 to 32 percent, and the majority of these patients undergo thyroid surgery. However, most patients (75 to 95 percent) undergo surgery for what is ultimately confirmed to be benign disease (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Follicular lesion or atypia of undetermined significance'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27\">",
"     'Follicular neoplasm'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Improvement in the assessment of indeterminate FNA results may allow better risk stratification. There are two approaches to the molecular characterization of FNA aspirates that are commercially available in the United States: identification of particular molecular markers of malignancy, such as BRAF and RAS mutational status, and use of high density genomic data for molecular classification (an FNA-trained mRNA classifier) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/38\">",
"     38",
"    </a>",
"    ]. The mRNA classifier measures the activity level of 167 genes within the nodule (using the FNA aspirate). We favor using an mRNA classifier system (gene expresser classifier), when available, based upon the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 513 indeterminate samples from 479 patients tested for BRAF, RAS,",
"      <span class=\"nowrap\">",
"       RET/PTC,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       PAX8/PPARgamma",
"      </span>",
"      mutations prior to surgery, the detection of any mutation conferred a risk of histologic malignancy of 88 and 87 percent for samples showing follicular",
"      <span class=\"nowrap\">",
"       lesion/atypia",
"      </span>",
"      of undetermined significance and follicular neoplasm, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/39\">",
"       39",
"      </a>",
"      ]. However, 6 and 14 percent of nodules with FNA showing follicular",
"      <span class=\"nowrap\">",
"       lesion/atypia",
"      </span>",
"      of undetermined significance and follicular neoplasm, respectively, were negative for these mutations and proved to be cancer on surgical histology. Thus, this approach misses a significant proportion of malignant samples that do not contain one of the mutations being tested.",
"     </li>",
"     <li>",
"      In a study of 265 indeterminate nodules (85 of which were malignant), using mRNA expression analysis and a gene expression classifier trained on FNA samples to detect benign thyroid nodules, the classifier had a negative predictive value for malignancy of 95 and 94 percent for samples showing follicular",
"      <span class=\"nowrap\">",
"       lesion/atypia",
"      </span>",
"      of undetermined significance and follicular neoplasm, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. It is suggested that application of this classifier would save over 60 percent of patients from diagnostic thyroid surgery, which would result in overall lower costs [",
"      <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Where available, we suggest using this classifier for evaluating patients with FNA cytology showing follicular",
"    <span class=\"nowrap\">",
"     lesion/atypia",
"    </span>",
"    of undetermined significance or follicular neoplasm. The decision to observe a patient with a benign molecular profile using this classifier should be reassessed as more data become available. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Follicular neoplasm'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Serum calcitonin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine measurement of serum calcitonin in patients with nodular thyroid disease is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/43\">",
"     43",
"    </a>",
"    ]. Several reports have suggested that serum calcitonin should be measured routinely in patients with nodular thyroid disease in order to identify those who have medullary thyroid cancer at an earlier stage and to improve survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/44-49\">",
"     44-49",
"    </a>",
"    ]. However, controversy remains about the routine use of serum calcitonin measurements because of the absence of uniform calcitonin thresholds to distinguish sporadic occult MTC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/49-51\">",
"     49-51",
"    </a>",
"    ], the high false-positive rate (59 percent or higher) in some studies, and the uncertain importance of small tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/9,52\">",
"     9,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=see_link\">",
"     \"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\", section on 'Medullary thyroid cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on the utility of routine serum calcitonin measurement in patients with nodular thyroid disease are largely from prospective cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/44-49,53-57\">",
"     44-49,53-57",
"    </a>",
"    ]. In various reports, basal serum CT was increased in 0.5 to 5 percent of patients with thyroid nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/48,54,57\">",
"     48,54,57",
"    </a>",
"    ]. In a study of 1167 French patients with nodular thyroid disease, the prevalence of MTC in patients with elevated versus normal basal CT levels was 41.1 and 0.17 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the studies that showed a diagnostic advantage to measuring basal serum calcitonin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/45,48,58,59\">",
"     45,48,58,59",
"    </a>",
"    ], however, serum calcitonin was repeated after pentagastrin (available only in some countries) stimulation to confirm medullary cancer or C cell hyperplasia in those with elevated calcitonin levels. As an example, in one report of 10,864 patients screened after 1991, 44 (0.4 percent) had an elevated calcitonin, all confirmed by an elevated pentagastrin-stimulated calcitonin, and all had medullary cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/48\">",
"     48",
"    </a>",
"    ]. Fifty-nine percent of these patients were in complete remission compared with only 2.7 percent of patients diagnosed with medullary cancer prior to the use of routine screening, suggesting a benefit to early diagnosis. In contrast, in a study of 10,158 patients with thyroid nodules, 5 percent had elevated basal calcitonin, but only 20 percent of these patients had elevated values after pentagastrin stimulation, and only 31 percent of these patients had medullary cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/54\">",
"     54",
"    </a>",
"    ]. In all of these studies, calcitonin was more accurate than FNA for indentifying medullary thyroid cancer, since many of the cancers were quite small. In the French study, only 2 of 12 patients diagnosed by calcitonin measurement had lesions that were 1.0 cm in diameter or larger, while four were less than 0.3 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    False-positive calcitonin results may be obtained in patients with hypercalcemia, hypergastrinemia, neuroendocrine tumors, renal insufficiency, papillary and follicular thyroid carcinomas, goiter, and chronic autoimmune thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/9,60\">",
"     9,60",
"    </a>",
"    ]. Furthermore, prolonged treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    (greater than two to four months), beta-blockers, and glucocorticoids have been associated with hypercalcitoninemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/61\">",
"     61",
"    </a>",
"    ]. In addition, there are reports of rare medullary thyroid cancers that do not secrete calcitonin, and a false negative test result may be expected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In countries where pentagastrin is available, basal serum CT screening for patients with thyroid nodular disease is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/43,45,48,59,64\">",
"     43,45,48,59,64",
"    </a>",
"    ]. At present, we agree with others that the routine use of basal calcitonin measurements in nodular thyroid disease is not warranted in countries (eg, United States) where the use of pentagastrin stimulation as a confirmatory test is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The American Thyroid Association (ATA) notes the uncertainties surrounding calcitonin measurements and has not taken a position for or against calcitonin screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/10,67\">",
"     10,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If pentagastrin stimulation testing were available, some thyroid experts would routinely measure serum calcitonin in patients with nodular thyroid disease, whereas others would not. If the basal serum calcitonin (CT) level is measured and exceeds 10",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    the CT measurement should be repeated after pentagastrin stimulation testing (after renal insufficiency and use of proton pump inhibitor medication have been ruled out) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/59\">",
"     59",
"    </a>",
"    ]. Calcium is also a calcitonin secretagogue, and owing to the unavailability of pentagastrin in many countries, there is a growing interest in using the calcium stimulation test as a confirmatory test in patients with elevated basal calcitonin levels. However, few standardized data using modern calcitonin assays are available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/68\">",
"     68",
"    </a>",
"    ]. Pentagastrin and calcium stimulation testing is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link&amp;anchor=H1624290#H1624290\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\", section on 'Pentagastrin stimulation test'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link&amp;anchor=H3039577#H3039577\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\", section on 'Calcium stimulation test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other lab tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine measurement of serum anti-thyroid peroxidase (TPO) antibodies and thyroglobulin is not necessary.",
"   </p>",
"   <p>",
"    Measurement of TPO antibodies may be helpful in patients with a high TSH suggestive of chronic autoimmune (Hashimoto's) thyroiditis. However, the presence of a high titer of TPO antibodies does not negate the need for FNA biopsy of a thyroid nodule in a patient with Hashimoto's thyroiditis. Although rapid shrinkage of the nodule when T4 therapy is instituted may be sufficiently reassuring to mitigate further concern, thyroiditis and thyroid cancer coexist with sufficient frequency, especially after head and neck irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/55,69\">",
"     55,69",
"    </a>",
"    ]. Thus, a definite nodule, even in the presence of a high serum antibody concentration, requires further evaluation.",
"   </p>",
"   <p>",
"    Serum thyroglobulin levels can be elevated in many thyroid diseases. An elevated level does not help discriminate benign from malignant thyroid nodules. Thus, we do not measure serum thyroglobulin levels as part of the evaluation of patients with a thyroid nodule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Thyroid incidentalomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incidentalomas are nonpalpable thyroid nodules that are detected during other imaging procedures. Nonpalpable nodules have approximately the same risk of malignancy as palpable nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. In some settings, especially nodules discovered on PET scan (see",
"    <a class=\"local\" href=\"#H20\">",
"     'PET scans'",
"    </a>",
"    below), the risk of malignancy may be higher, but in other settings (cystic nodules), it may be lower.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Patients with a history of childhood head or neck irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation exposure of the thyroid during childhood is the most clearly defined environmental factor associated with benign and malignant thyroid tumors. There is a linear dose-response curve, with no evidence of a threshold at low doses. The risk reaches a plateau, and possibly tapers off, at high doses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=see_link\">",
"     \"Radiation-induced thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with a history of radiation exposure during childhood have nonpalpable thyroid nodules. This was illustrated by a report in which 54 such patients underwent thyroid ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/70\">",
"     70",
"    </a>",
"    ]. Although most of the patients had no palpable nodules, 47 had 157 nodules on ultrasonography. The nodules ranged in size from a few millimeters to 3.0 cm. Eleven nodules were 1.5 cm or larger, six of which could be palpated.",
"   </p>",
"   <p>",
"    The arguments for and against the routine use of ultrasonography in patients with a history of radiation are reviewed in detail elsewhere. We recommend ultrasonography based upon an assessment of each patient's risk factors for thyroid cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=see_link&amp;anchor=H7#H7\">",
"     \"Radiation-induced thyroid cancer\", section on 'Ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Nonthyroid cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a nonthyroid cancer, there may be a higher than usual incidence of malignancy in incidentally discovered thyroid nodules. In one report of 41 such patients, 16 underwent surgery based upon the results of FNA, with four papillary thyroid cancers, four microscopic papillary thyroid cancers, two metastatic cancers, and seven benign lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     PET scans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many incidentalomas found on PET scans are thyroid cancers; in two studies, 2.2 to 2.8 percent of patients had thyroid uptake, and 27 to 42 percent of those proved to be papillary cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/72\">",
"     72",
"    </a>",
"    ]. In a retrospective study of 87 incidentalomas identified by PET, 76 percent of those with suspicious ultrasonographic characteristics were malignant, while only 13 percent of those with benign ultrasonographic characteristics were cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/73\">",
"     73",
"    </a>",
"    ]. Medullary cancer has also been detected as an incidental finding on PET scan [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Thus, thyroid nodules discovered incidentally on PET scans require ultrasound-guided FNA biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Graves' disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of thyroid nodules and cancer in patients with Graves' disease has been investigated in a prospective study in which 245 patients with Graves' underwent screening ultrasonography. Thirty-five percent had nodules and 3.3 percent had thyroid cancers (one of eight cancers was palpable) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/76\">",
"     76",
"    </a>",
"    ]. The authors did not recommend routine ultrasonography in patients with Graves' disease, but noted the risk of malignancy was higher in patients over age 45. We limit ultrasonography to Graves' patients with palpable abnormalities or heterogeneous or focal decreased uptake on thyroid scintigraphy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cystic nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is disagreement concerning the risk of cancer in a cystic nodule. Several series have reported few (0.5 to 3 percent) or no cancers in these nodules, while others have reported rates of cancer only slightly lower than those for solid nodules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37111?source=see_link\">",
"     \"Cystic thyroid nodules\"",
"    </a>",
"    .) As a result, aspiration of cyst fluid for cytologic analysis is almost always indicated for complex cysts &gt;2cm in diameter without suspicious features. FNA is not necessary for pure cysts unless it is for therapeutic reasons. Cancer is uncommon in cystic nodules that are no longer palpable after aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/77\">",
"     77",
"    </a>",
"    ]. Larger nodules, nodules with bloody aspirates, or nodules that reaccumulate after repeated aspiration are more likely to contain cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Reaspiration should be performed if the nodule remains palpable after aspiration and the cytology is nondiagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasonography after aspiration is useful for determining the nature, size, and location of the solid portion of the nodule, which then can be aspirated under ultrasound guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who refuse FNA, or when there is concern about a hematoma in patients taking anticoagulants, clinical follow-up of the nodule is reasonable if there is evidence of extensive cystic degeneration on ultrasonography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid radionuclide scanning is contraindicated during pregnancy. Otherwise, a pregnant woman found to have a thyroid nodule should be evaluated in the same way as if she were not pregnant. Thus, fine needle aspiration biopsy of the nodule should be done (as it would be for most nonpregnant patients). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Goiter'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy for patients with thyroid nodules varies with the lesion that is found and whether or not it is functioning. There are six major categories of results that are obtained from FNA, each of which indicates different subsequent management (",
"    <a class=\"graphic graphic_figure graphicRef72400 \" href=\"UTD.htm?38/34/39470\">",
"     figure 1",
"    </a>",
"    ). The diagnostic categories and cytopathologic diagnoses of FNA results are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28056?source=see_link&amp;anchor=H11#H11\">",
"     \"Thyroid biopsy\", section on 'Diagnostic categories'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24452?source=see_link\">",
"     \"Atlas of thyroid cytopathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Benign nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with benign nodules (macrofollicular or",
"    <span class=\"nowrap\">",
"     adenomatoid/hyperplastic",
"    </span>",
"    nodules, colloid adenomas, nodular goiter, and Hashimoto's thyroiditis) are usually followed without surgery. There is still controversy concerning the efficacy of T4 therapy for these patients. In the absence of a history of childhood neck irradiation, patients with benign nodules should not be treated with T4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=see_link\">",
"     \"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We perform periodic ultrasound monitoring of benign thyroid nodules, initially at 6 to 12 months, then at increasing intervals over time. Cystic degeneration and hemorrhage are the most common causes of sudden enlargement, and can be detected by ultrasonography or repeat aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/28\">",
"     28",
"    </a>",
"    ]. Reaspiration of thyroid nodules that are unchanged clinically is not warranted, because detection of malignancy is uncommon in routine repeat biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/83-87\">",
"     83-87",
"    </a>",
"    ]. This was illustrated in two studies of 250 patients who had routine repeat FNA; only one previously benign nodule was found to be malignant on repeat aspiration (0.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. In a third report, 3 of 216 patients (1.4 percent) had papillary cancer on a repeat biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malignancy is rare even in benign thyroid nodules that have grown. In an observational study of 268 patients with 330 benign thyroid nodules, most nodules (89 percent) increased in volume (defined as &ge;15 percent increase on ultrasound) over a mean of 20 months (range 1 to 65 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/88\">",
"     88",
"    </a>",
"    ]. However, only 1 of the 74 nodules that were rebiopsied was malignant (1.4 percent).",
"   </p>",
"   <p>",
"    Thus, small changes in nodule size on serial ultrasonography do not require a repeat aspiration. However, reassessment is warranted when there is substantial growth (more than a 50 percent change in volume or 20 percent increase in nodule diameter with a minimum increase in two or more dimensions of at least 2 mm) or change in the texture of a nodule, or new symptoms are attributed to a nodule [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Follicular lesion or atypia of undetermined significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;This category includes lesions with mild nuclear atypia, mixed macrofollicular and microfollicular lesions where the proportion of microfollicles and macrofollicles is similar, lesions with extensive oncocytic (H&uuml;rthle cell) change, and specimens that are compromised because of poor fixation or obscuring blood. These cytologic findings are common, especially in nodular goiters. The risk of malignancy with this cytologic classification ranges from 5 to 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/37,89-91\">",
"     37,89-91",
"    </a>",
"    ]. There is no definite consensus as to which of these should be excised to exclude follicular cancer.",
"   </p>",
"   <p>",
"    One approach is to follow patients with nodules that are greater than 50 percent macrofollicular fragments (flat sheets with uniform non-crowded cells), unless they are clinically suspicious or present in patients with a higher risk of cancer. Nodules that are less than 50 percent macrofollicular fragments, nodules with similar proportions of macrofollicles and microfollicles, and nodules with cellular atypia are frequently reaspirated after a three to six month interval, or earlier, before making a decision whether to monitor or excise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/37\">",
"     37",
"    </a>",
"    ]. If repeat aspirates continue to show atypical cells or microfollicularity, thyroid scintigraphy (for microfollicularity), surgery, or molecular testing (as for follicular neoplasm) should be considered (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Follicular neoplasm'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Previously, the response of a nodule to T4 suppressive therapy was used to select nodules that required excision: nodules that shrank were assumed to be benign, and those that failed to shrink were excised to exclude malignancy. However, this approach is not very specific since only 17 to 25 percent of nodules regress when T4 is administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=see_link\">",
"     \"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter\"",
"    </a>",
"    .) Furthermore, 13 percent of subsequently proven papillary cancers in one series decreased in size during T4 treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Follicular neoplasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with cytology suggesting follicular neoplasms (microfollicular, cellular, or indeterminate), we typically perform thyroid scintigraphy, particularly if the TSH is in the lower end of the normal range. Patients with hyperfunctioning (autonomous) nodules are followed, or if the patient is hyperthyroid, radioiodine therapy or surgery is advised. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"     \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    From 15 to 25 percent of microfollicular or cellular adenomas prove to be cancers, depending upon the cytologic pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/37\">",
"     37",
"    </a>",
"    ]. Thus, most patients with nonautonomous microfollicular adenomas should undergo diagnostic surgery with pathology evaluation for capsular or vascular invasion. Patients with surgical histology specimens showing benign follicular adenoma (ie, the absence of capsular or vascular invasion) do not require further treatment. However, patients whose surgical histology shows follicular thyroid cancer (or follicular variant papillary thyroid cancer) will need to have a completion thyroidectomy.",
"   </p>",
"   <p>",
"    Several approaches are under investigation to improve upon cytology alone for the assessment of follicular neoplasm and follicular",
"    <span class=\"nowrap\">",
"     lesion/atypia",
"    </span>",
"    of undetermined significance. The routine use of molecular analysis on indeterminate FNA aspirates (follicular neoplasm or follicular",
"    <span class=\"nowrap\">",
"     lesion/atypia",
"    </span>",
"    of undetermined significance) may reduce substantially the number of patients who require diagnostic thyroid surgery. (See",
"    <a class=\"local\" href=\"#H450947\">",
"     'Molecular markers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Where available, we suggest mRNA expression analysis using an FNA-trained classifier for managing patients with FNA cytology showing follicular neoplasm or follicular",
"    <span class=\"nowrap\">",
"     lesion/atypia",
"    </span>",
"    of undetermined significance. (See",
"    <a class=\"local\" href=\"#H450947\">",
"     'Molecular markers'",
"    </a>",
"    above.) For patients with indeterminate FNA cytology who have a benign molecular pattern, we suggest observation, rather than diagnostic lobectomy. The negative predictive value for malignancy with this technique (94 to 95 percent) seems to be sufficiently high to warrant observation over diagnostic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, the decision to observe a patient with a benign profile should be reassessed as more data become available. For patients with a suspicious pattern using this technique, we suggest a diagnostic lobectomy (however, an individual patient may prefer a total thyroidectomy if a high volume thyroid surgeon is available).",
"   </p>",
"   <p>",
"    If the fine needle aspirate is analyzed for particular molecular markers of malignancy (rather than mRNA expression analysis using an FNA-trained classifier), surgical management depends upon the findings. For patients with indeterminate FNA cytology who test negative for a mutation using a molecular panel that tests for BRAF, RAS,",
"    <span class=\"nowrap\">",
"     RET/PTC,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     PAX8/PPARgamma",
"    </span>",
"    mutations, we &nbsp;diagnostic lobectomy, rather than observation. A significant proportion of malignant samples (6 to 14 percent) will be missed using this technique, if the aspirate does not contain one of the mutations being tested. (See",
"    <a class=\"local\" href=\"#H450947\">",
"     'Molecular markers'",
"    </a>",
"    above.) For patients with indeterminate cytology who test positive for a mutation using this molecular panel, we suggest a total thyroidectomy rather than a diagnostic lobectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H6#H6\">",
"     \"Surgical treatment of differentiated thyroid cancer\", section on 'Choice of procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Suspicious for malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This category includes lesions with some features suggestive of but not definitive for papillary thyroid cancer. Typically, nodules in this category have a 50 to 75 percent risk of malignancy. Such patients should be referred for surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Malignant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant category includes papillary cancer, medullary cancer, thyroid lymphoma, anaplastic cancer, and cancer metastatic to the thyroid. Patients with cytology diagnostic of malignancy should be referred for surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Nondiagnostic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nondiagnostic biopsy is cytologically inadequate. It is critical that the absence of malignant cells not be interpreted as a negative biopsy if no or scant follicular tissue is obtained. In a study of patients with a nondiagnostic cytology specimen after a palpation FNA, repeating the FNA under ultrasound guidance significantly improved the diagnostic yield for both solid and cystic nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/93\">",
"     93",
"    </a>",
"    ]. Thus, for patients with nondiagnostic FNA biopsies, we repeat the FNA using ultrasound-guidance. If repeated ultrasound-guided aspirations are nondiagnostic, ultrasound-guided core needle biopsy should be considered. In one study of patients who had one non-diagnostic FNA, a core-needle biopsy provided diagnostic results in 74 percent of patients, while a repeat FNA provided a result in only 52 percent of patients; after two non-diagnostic FNAs, the core needle provided a result in 86 versus 29 percent for FNA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/94\">",
"     94",
"    </a>",
"    ]. Surgical excision, especially for larger solid nodules with sonographically suspicious features [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/95\">",
"     95",
"    </a>",
"    ], or observation, especially for smaller partially cystic nodules, are reasonable options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Autonomous nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy of patients with autonomous nodules is controversial. Those in whom the nodule causes hyperthyroidism should be treated with radioiodine or surgery, possibly after a period of antithyroid drug therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"     \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with subclinical hyperthyroidism (low serum TSH and normal serum free T4 values) present a difficult problem. Subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation in patients over age 60 to 65 years, and in postmenopausal women, a decrease in bone mineral density. Management depends upon clinical risk for complications of subclinical hyperthyroidism and the degree of TSH suppression. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"     \"Subclinical hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Cystic thyroid nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic nodules also present difficult management issues. Many patients with small cystic nodules with nondiagnostic cytology can be followed with the assumption that the nodule is benign. In some patients, however, recurrent bleeding or cyst reformation may be a source of discomfort, anxiety, or rarely obstructive symptoms, mandating excision of the nodule. T4 therapy was not beneficial in a small randomized study of patients with cystic nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?27/53/28506/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37111?source=see_link\">",
"     \"Cystic thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Ablation techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign, autonomous, and cystic thyroid nodules can be treated by ultrasound-guided injection of ethanol or sclerosing agents, and by ultrasound-directed physical energy. These approaches have not gained widespread acceptance in the United States because of potential complications, including occasional reports of prolonged pain after the procedure. This topic is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31814?source=see_link\">",
"     \"Ultrasound-guided thyroid biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23618?source=see_link\">",
"       \"Patient information: Thyroid nodules (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/12/30914?source=see_link\">",
"       \"Patient information: Multinodular goiter (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/16/18691?source=see_link\">",
"       \"Patient information: Thyroid nodules (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial evaluation in all patients with a thyroid nodule (discovered either by palpation or incidentally noted on a radiologic procedure, such as carotid ultrasonography, neck CT, or PET) includes a history, physical examination, neck ultrasonography, and measurement of serum thyroid stimulating hormone (TSH). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thyroid scintigraphy should be performed in patients with a low serum TSH concentration. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Thyroid scintigraphy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fine needle aspiration (FNA) biopsy is the most accurate method for evaluating thyroid nodules and selecting patients for thyroid surgery (",
"      <a class=\"graphic graphic_algorithm graphicRef75103 \" href=\"UTD.htm?3/27/3504\">",
"       algorithm 1",
"      </a>",
"      ). We suggest FNA biopsy of palpable and incidentally discovered (nonpalpable) solid hypoechoic thyroid nodules &gt;1 cm. Solid isoechoic or hyperechoic nodules &ge;1 to 1.5 cm, mixed cystic and solid nodules with suspicious ultrasound characteristics &ge;1.5 to 2 cm, and mixed cystic and solid nodules with no suspicious features &ge;2 cm should also have FNA (",
"      <a class=\"graphic graphic_table graphicRef70513 \" href=\"UTD.htm?2/6/2157\">",
"       table 3",
"      </a>",
"      ). Spongiform nodules &ge;2 cm could also be evaluated by FNA, although observation without FNA is an alternative option. We perform FNA biopsy of subcentimeter nodules only if they have highly suspicious characteristics on ultrasound. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FNA biopsy of thyroid nodules is commonly performed under ultrasound guidance. Ultrasound-guided FNA biopsy should be performed for nonpalpable nodules and for nodules that are technically difficult to aspirate using palpation methods alone, such as predominantly cystic or posteriorly located nodules. In patients with large nodules (&gt;4 cm), ultrasound-guided FNA directed at several areas within the nodule may reduce the risk of a false negative biopsy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Fine needle aspiration biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Where available, we suggest mRNA expression analysis using an FNA-trained gene classifier for further evaluating FNA aspirates with indeterminate cytology (follicular neoplasm or follicular",
"      <span class=\"nowrap\">",
"       lesion/atypia",
"      </span>",
"      of undetermined significance). (See",
"      <a class=\"local\" href=\"#H450947\">",
"       'Molecular markers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with benign nodules (macrofollicular or",
"      <span class=\"nowrap\">",
"       adenomatoid/hyperplastic",
"      </span>",
"      nodules, colloid adenomas, nodular goiter, and Hashimoto's thyroiditis) are usually followed without surgery. We perform periodic ultrasound monitoring of benign thyroid nodules initially at 6 to 12 months, then at increasing intervals, and repeat FNA only when there is substantial growth (more than a 50 percent change in volume or 20 percent increase in at least two nodule dimensions), change in the echo texture of a nodule, or new symptoms are attributed to a nodule. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Benign nodules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with follicular lesions or atypia of undetermined significance (nodules with atypical cells or nodules with both macrofollicular and microfollicular features), we perform repeat FNA after a three to six month interval, or earlier. If repeat aspirates continue to show follicular",
"      <span class=\"nowrap\">",
"       lesion/atypia",
"      </span>",
"      of undetermined significance, and thyroid scintigraphy does not show an autonomous nodule, we perform molecular testing (as for follicular neoplasm immediately below). If molecular testing is unavailable, we suggest surgical resection if repeat aspirates continue to show atypical cells (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with nodules that are greater than 50 percent macrofollicular, we suggest monitoring, unless they are clinically suspicious or present in patients with a higher risk of cancer (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Follicular lesion or atypia of undetermined significance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with nonautonomous (cold) follicular neoplasms (microfollicular adenomas), we send the FNA aspirate for mRNA expression analysis using an FNA-trained gene classifier (if available). If molecular testing is not available, we suggest diagnostic lobectomy, rather than observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In the absence of capsular or vascular invasion (on surgical histology), the lesion is classified as a benign adenoma, and no further treatment is required. For patients whose surgical histology shows follicular thyroid",
"      <strong>",
"      </strong>",
"      cancer (or follicular variant papillary thyroid cancer), completion thyroidectomy is necessary. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Follicular neoplasm'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H450947\">",
"       'Molecular markers'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with indeterminate FNA cytology who have a benign molecular pattern on mRNA expression analysis using an FNA-trained gene classifier, we suggest observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, the decision to observe a patient with a benign profile should be reassessed as more data become available. Diagnostic lobectomy remains an alternative option for patients with a benign molecular pattern, depending upon the nodule&rsquo;s clinical characteristics and patient preference. For patients with a suspicious molecular pattern using this technique, diagnostic lobectomy is necessary. However, an individual patient may prefer a total thyroidectomy if a high volume thyroid surgeon is available.",
"      <br/>",
"      <br/>",
"      If the FNA aspirate (from a patient with indeterminate cytology) is tested for a mutation using a molecular panel that tests for BRAF, RAS,",
"      <span class=\"nowrap\">",
"       RET/PTC,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       PAX8/PPARgamma",
"      </span>",
"      mutations, and no mutations are detected, we suggest diagnostic lobectomy rather than observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A significant proportion of malignant samples will be missed using this technique if the aspirate does not contain one of the mutations being tested. For patients with indeterminate cytology who test positive for a mutation using this molecular panel, we suggest a total thyroidectomy, rather than a diagnostic lobectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with cytology suggesting cancer or suspicious for cancer should be referred for surgery. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Malignant'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Suspicious for malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with nondiagnostic palpation or ultrasound-guided biopsies, we perform repeat FNA using ultrasound-guidance. For patients with",
"      <strong>",
"      </strong>",
"      solid nodules and nondiagnostic cytology after repeated biopsies, we typically perform an ultrasound-guided core needle biopsy. Careful clinical follow-up, repeat FNA biopsy, and surgical resection are alternative options. For cytologically nondiagnostic nodules that are partially cystic, we suggest careful clinical follow-up with ultrasound monitoring rather than surgical resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Nondiagnostic'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37111?source=see_link\">",
"       \"Cystic thyroid nodules\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/1\">",
"      Werk EE Jr, Vernon BM, Gonzalez JJ, et al. Cancer in thyroid nodules. A community hospital survey. Arch Intern Med 1984; 144:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/2\">",
"      Belfiore A, Giuffrida D, La Rosa GL, et al. High frequency of cancer in cold thyroid nodules occurring at young age. Acta Endocrinol (Copenh) 1989; 121:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/3\">",
"      Heged&uuml;s L. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/4\">",
"      Lin JD, Chao TC, Huang BY, et al. Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. Thyroid 2005; 15:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/5\">",
"      Steele SR, Martin MJ, Mullenix PS, et al. The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography. Arch Surg 2005; 140:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/6\">",
"      Hagag P, Strauss S, Weiss M. Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid 1998; 8:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/7\">",
"      Leenhardt L, Hejblum G, Franc B, et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab 1999; 84:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/8\">",
"      Nam-Goong IS, Kim HY, Gong G, et al. Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 2004; 60:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/9\">",
"      Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med 2005; 142:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/10\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/11\">",
"      Boelaert K, Horacek J, Holder RL, et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 2006; 91:4295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/12\">",
"      Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008; 93:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/13\">",
"      Solbiati L, Volterrani L, Rizzatto G, et al. The thyroid gland with low uptake lesions: evaluation by ultrasound. Radiology 1985; 155:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/14\">",
"      Radecki PD, Arger PH, Arenson RL, et al. Thyroid imaging: comparison of high-resolution real-time ultrasound and computed tomography. Radiology 1984; 153:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/15\">",
"      Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997; 126:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/16\">",
"      Marqusee E, Benson CB, Frates MC, et al. Usefulness of ultrasonography in the management of nodular thyroid disease. Ann Intern Med 2000; 133:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/17\">",
"      Reschini E, Ferrari C, Castellani M, et al. The trapping-only nodules of the thyroid gland: prevalence study. Thyroid 2006; 16:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/18\">",
"      Dige-Petersen H, Kroon S, Vadstrup S, et al. A comparison of 99Tc and 123I scintigraphy in nodular thyroid disorders. Eur J Nucl Med 1978; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/19\">",
"      Shambaugh GE 3rd, Quinn JL, Oyasu R, Freinkel N. Disparate thyroid imaging. Combined studies with sodium pertechnetate Tc 99m and radioactive iodine. JAMA 1974; 228:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/20\">",
"      Tennvall J, Cederquist E, M&ouml;ller T, et al. Preoperative scintigraphy with correlation to cytology and histopathology in carcinoma of the thyroid. Acta Radiol Oncol 1983; 22:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/21\">",
"      Turner JW, Spencer RP. Thyroid carcinoma presenting as a pertechnetate \"hot\" nodule, but without 131I uptake: case report. J Nucl Med 1976; 17:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/22\">",
"      Arnold JE, Pinsky S. Comparison of 99mTc and 123I for thyroid imaging. J Nucl Med 1976; 17:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/23\">",
"      Blum M, Goldman AB. Improved diagnosis of \"nondelineated\" thyroid nodules by oblique scintillation scanning and echography. J Nucl Med 1975; 16:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/24\">",
"      Nelson RL, Wahner HW, Gorman CA. Rectilinear thyroid scanning as a predictor of malignancy. Ann Intern Med 1978; 88:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/25\">",
"      Miller JM. Re: thyroid carcinoma in an autonomously functioning nodule. J Nucl Med 1980; 21:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/26\">",
"      Hoving J, Piers DA, Vermey A, Oosterhuis JW. Carcinoma in hyperfunctioning thyroid nodule in recurrent hyperthyroidism. Eur J Nucl Med 1981; 6:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/27\">",
"      Hayes FJ, Sheahan K, Heffernan A, McKenna TJ. Aggressive thyroid cancer associated with toxic nodular goitre. Eur J Endocrinol 1996; 134:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/28\">",
"      Ashcraft MW, Van Herle AJ. Management of thyroid nodules. II: Scanning techniques, thyroid suppressive therapy, and fine needle aspiration. Head Neck Surg 1981; 3:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/29\">",
"      Molitch ME, Beck JR, Dreisman M, et al. The cold thyroid nodule: an analysis of diagnostic and therapeutic options. Endocr Rev 1984; 5:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/30\">",
"      Ramos CD, Zantut-Wittmann DE, Tambascia MA, et al. Thyroid suppression test with L-thyroxine and [99mTc] pertechnetate. Clin Endocrinol (Oxf) 2000; 52:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/31\">",
"      Miller JM, Hamburger JI, Kini S. Diagnosis of thyroid nodules. Use of fine-needle aspiration and needle biopsy. JAMA 1979; 241:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/32\">",
"      Hamberger, B, Gharib, H, Melton, LJ III, et al. Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. Am J Med 1982; 73:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/33\">",
"      Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002; 87:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/34\">",
"      McCartney CR, Stukenborg GJ. Decision analysis of discordant thyroid nodule biopsy guideline criteria. J Clin Endocrinol Metab 2008; 93:3037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/35\">",
"      Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 2009; 94:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/36\">",
"      Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003; 13:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/37\">",
"      Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008; 36:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/38\">",
"      Hodak SP, Rosenthal DS, erican Thyroid Association Clinical Affairs Committee. Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens. Thyroid 2013; 23:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/39\">",
"      Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011; 96:3390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/40\">",
"      Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab 2010; 95:5296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/41\">",
"      Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012; 367:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/42\">",
"      Li H, Robinson KA, Anton B, et al. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2011; 96:E1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/43\">",
"      Costante G, Filetti S. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease? Oncologist 2011; 16:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/44\">",
"      Horvit PK, Gagel RF. The goitrous patient with an elevated serum calcitonin--what to do? J Clin Endocrinol Metab 1997; 82:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/45\">",
"      Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 1997; 82:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/46\">",
"      Ozgen AG, Hamulu F, Bayraktar F, et al. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid 1999; 9:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/47\">",
"      Hahm JR, Lee MS, Min YK, et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001; 11:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/48\">",
"      Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/49\">",
"      Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007; 92:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/50\">",
"      Machens A, Hoffmann F, Sekulla C, Dralle H. Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer. Endocr Relat Cancer 2009; 16:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/51\">",
"      Chambon G, Alovisetti C, Idoux-Louche C, et al. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients. J Clin Endocrinol Metab 2011; 96:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/52\">",
"      Machens A, Dralle H. Biological relevance of medullary thyroid microcarcinoma. J Clin Endocrinol Metab 2012; 97:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/53\">",
"      Karanikas G, Moameni A, Poetzi C, et al. Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. J Clin Endocrinol Metab 2004; 89:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/54\">",
"      Vierhapper H, Niederle B, Bieglmayer C, et al. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 2005; 15:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/55\">",
"      Borget I, De Pouvourville G, Schlumberger M. Editorial: Calcitonin determination in patients with nodular thyroid disease. J Clin Endocrinol Metab 2007; 92:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/56\">",
"      Rink T, Truong PN, Schroth HJ, et al. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid 2009; 19:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/57\">",
"      Herrmann BL, Schmid KW, Goerges R, et al. Calcitonin screening and pentagastrin testing: predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease. Eur J Endocrinol 2010; 162:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/58\">",
"      Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994; 78:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/59\">",
"      Karges W, Dralle H, Raue F, et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/60\">",
"      Toledo SP, Louren&ccedil;o DM Jr, Santos MA, et al. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo) 2009; 64:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/61\">",
"      Erdogan MF, Gursoy A, Kulaksizoglu M. Long-term effects of elevated gastrin levels on calcitonin secretion. J Endocrinol Invest 2006; 29:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/62\">",
"      Wang TS, Ocal IT, Sosa JA, et al. Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma. Thyroid 2008; 18:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/63\">",
"      Dora JM, Canalli MH, Capp C, et al. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. Thyroid 2008; 18:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/64\">",
"      Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/65\">",
"      Hodak SP, Burman KD. The calcitonin conundrum--is it time for routine measurement of serum calcitonin in patients with thyroid nodules? J Clin Endocrinol Metab 2004; 89:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/66\">",
"      Daniels GH. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid 2011; 21:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/67\">",
"      American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/68\">",
"      Colombo C, Verga U, Mian C, et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J Clin Endocrinol Metab 2012; 97:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/69\">",
"      Clark OH. TSH suppression in the management of thyroid nodules and thyroid cancer. World J Surg 1981; 5:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/70\">",
"      Schneider AB, Bekerman C, Leland J, et al. Thyroid nodules in the follow-up of irradiated individuals: comparison of thyroid ultrasound with scanning and palpation. J Clin Endocrinol Metab 1997; 82:4020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/71\">",
"      Wilhelm SM, Robinson AV, Krishnamurthi SS, Reynolds HL. Evaluation and management of incidental thyroid nodules in patients with another primary malignancy. Surgery 2007; 142:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/72\">",
"      Kang KW, Kim SK, Kang HS, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003; 88:4100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/73\">",
"      Kwak JY, Kim EK, Yun M, et al. Thyroid incidentalomas identified by 18F-FDG PET: sonographic correlation. AJR Am J Roentgenol 2008; 191:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/74\">",
"      Van den Bruel A, Maes A, De Potter T, et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 2002; 87:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/75\">",
"      Nam SY, Roh JL, Kim JS, et al. Focal uptake of (18)F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol (Oxf) 2007; 67:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/76\">",
"      Kim WB, Han SM, Kim TY, et al. Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease. Clin Endocrinol (Oxf) 2004; 60:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/77\">",
"      Melliere D, Massin JP, Calmettes C, et al. [The risk of malignancy in cold thyroid nodules. 607 operated cases]. Presse Med 1970; 78:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/78\">",
"      Ma MK, Ong GB. Cystic thyroid nodules. Br J Surg 1975; 62:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/79\">",
"      La Rosa GL, Belfiore A, Giuffrida D, et al. Evaluation of the fine needle aspiration biopsy in the preoperative selection of cold thyroid nodules. Cancer 1991; 67:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/80\">",
"      Rosen IB, Provias JP, Walfish PG. Pathologic nature of cystic thyroid nodules selected for surgery by needle aspiration biopsy. Surgery 1986; 100:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/81\">",
"      Walfish PG, Hazani E, Strawbridge HT, et al. Combined ultrasound and needle aspiration cytology in the assessment and management of hypofunctioning thyroid nodule. Ann Intern Med 1977; 87:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/82\">",
"      Takashima S, Fukuda H, Kobayashi T. Thyroid nodules: clinical effect of ultrasound-guided fine-needle aspiration biopsy. J Clin Ultrasound 1994; 22:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/83\">",
"      Kuma K, Matsuzuka F, Yokozawa T, et al. Fate of untreated benign thyroid nodules: results of long-term follow-up. World J Surg 1994; 18:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/84\">",
"      Lucas A, Llatj&oacute;s M, Salinas I, et al. Fine-needle aspiration cytology of benign nodular thyroid disease. Value of re-aspiration. Eur J Endocrinol 1995; 132:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/85\">",
"      Merchant SH, Izquierdo R, Khurana KK. Is repeated fine-needle aspiration cytology useful in the management of patients with benign nodular thyroid disease? Thyroid 2000; 10:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/86\">",
"      Erdoan MF, Kamel N, Aras D, et al. Value of re-aspirations in benign nodular thyroid disease. Thyroid 1998; 8:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/87\">",
"      Orlandi A, Puscar A, Capriata E, Fideleff H. Repeated fine-needle aspiration of the thyroid in benign nodular thyroid disease: critical evaluation of long-term follow-up. Thyroid 2005; 15:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/88\">",
"      Alexander EK, Hurwitz S, Heering JP, et al. Natural history of benign solid and cystic thyroid nodules. Ann Intern Med 2003; 138:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/89\">",
"      Olson MT, Clark DP, Erozan YS, Ali SZ. Spectrum of risk of malignancy in subcategories of 'atypia of undetermined significance'. Acta Cytol 2011; 55:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/90\">",
"      Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer 2009; 117:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/91\">",
"      Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of \"follicular lesion of undetermined significance/atypia of undetermined significance\". Cancer Cytopathol 2010; 118:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/92\">",
"      Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/93\">",
"      Alexander EK, Heering JP, Benson CB, et al. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 2002; 87:4924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/94\">",
"      Samir AE, Vij A, Seale MK, et al. Ultrasound-guided percutaneous thyroid nodule core biopsy: clinical utility in patients with prior nondiagnostic fine-needle aspirate. Thyroid 2012; 22:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/95\">",
"      Moon HJ, Kwak JY, Choi YS, Kim EK. How to manage thyroid nodules with two consecutive non-diagnostic results on ultrasonography-guided fine-needle aspiration. World J Surg 2012; 36:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/53/28506/abstract/96\">",
"      McCowen KD, Reed JW, Fariss BL. The role of thyroid therapy in patients with thyroid cysts. Am J Med 1980; 68:853.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7890 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-DF5911362B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28506=[""].join("\n");
var outline_f27_53_28506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serum TSH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thyroid ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Thyroid scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nonfunctioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Autonomous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Indeterminate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fine needle aspiration biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Multiple nodules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Monitoring of small nodules that are not biopsied",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Diagnostic categories",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H450947\">",
"      - Molecular markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Serum calcitonin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other lab tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Thyroid incidentalomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Patients with a history of childhood head or neck irradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Nonthyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - PET scans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cystic nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Benign nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Follicular lesion or atypia of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Follicular neoplasm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Suspicious for malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Malignant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Nondiagnostic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Autonomous nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Cystic thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Ablation techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7890\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7890|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?3/27/3504\" title=\"algorithm 1\">",
"      Algorithm for management of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7890|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/18/5409\" title=\"diagnostic image 1\">",
"      Nonfunctioning thyroid nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/16/41216\" title=\"diagnostic image 2\">",
"      Indeterminate thyroid nodule scan I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/33/14879\" title=\"diagnostic image 3\">",
"      Indeterminate thyroid nodule scan II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/62/28655\" title=\"diagnostic image 4\">",
"      Thyroid suppression scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7890|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/34/39470\" title=\"figure 1\">",
"      Evaluation of patients with a thyroid nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7890|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/34/4655\" title=\"picture 1\">",
"      Autonomous thyroid nodule scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7890|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/25/8604\" title=\"table 1\">",
"      Major causes of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/17/20763\" title=\"table 2\">",
"      Ultrasound features associated with thyroid cancer risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/6/2157\" title=\"table 3\">",
"      Indications FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/60/5068\" title=\"table 4\">",
"      Cytology of follicular thyroid lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24452?source=related_link\">",
"      Atlas of thyroid cytopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37111?source=related_link\">",
"      Cystic thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=related_link\">",
"      Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1990?source=related_link\">",
"      Overview of thyroid nodule formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/12/30914?source=related_link\">",
"      Patient information: Multinodular goiter (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/16/18691?source=related_link\">",
"      Patient information: Thyroid nodules (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23618?source=related_link\">",
"      Patient information: Thyroid nodules (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=related_link\">",
"      Radiation-induced thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=related_link\">",
"      Surgical treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28056?source=related_link\">",
"      Thyroid biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=related_link\">",
"      Thyroid hormone suppressive therapy for thyroid nodules and benign goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=related_link\">",
"      Treatment of toxic adenoma and toxic multinodular goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31814?source=related_link\">",
"      Ultrasound-guided thyroid biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_53_28507="Beta thal intermedia variants";
var content_f27_53_28507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Thalassemia variants which may present as Beta Thalassemia intermedia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         General principles:",
"        </strong>",
"        The pathophysiology of beta thalassemia depends absolutely on the amount of excess unpaired alpha globin chains. Therefore any genetic variant that increases or decreases the amount of these unpaired alpha chains (eg, by altering the rate of alpha or beta chain production, or by substituting for the missing beta chains) will modify the phenotype. Disorders that present as &beta;-thalassemia intermedia, rather than as the major or minor variants, are listed below:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homozygosity for mild forms of &beta;+ thalassemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Compound heterozygosity for &beta;+/&beta;&ordm; thalassemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Compound heterozygosity for &beta; thalassemia and",
"another beta chain variant (eg, &beta;-thal/Hgb E)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coinheritance of homozygous &beta; thalassemia with",
"genes for increased gamma chain synthesis (ie, HPFH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coinheritance of homozygous &beta;+ thalassemia",
"with alpha thalassemia (eg, &beta;+/&beta;+ with -a/-a, --/aa,",
"-a/aa, or --/-a)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coinheritance of heterozygous &beta; thalassemia",
"and triplicated or quadruplicated alpha genes (eg, aa/aaa or aa/aaaa)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dominant forms of beta thalassemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     &beta; &ordm; thalassemia: no production of beta chains; &beta; + thalassemia: reduced production of beta chains (may be mild, moderate, or severely reduced); HPFH: Hereditary persistence of fetal hemoglobin.",
"    </div>",
"    <div class=\"reference\">",
"     Table provided by Stanley L. Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28507=[""].join("\n");
var outline_f27_53_28507=null;
var title_f27_53_28508="Causes of occupational asthma";
var content_f27_53_28508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of occupational asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Occupation at risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Low molecular weight chemicals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isocyanates (eg, toluene diisocyanate, diphenylmethane diisocyanate, hexamethylene diisocyanate, naphthalene diisocyanate)",
"       </td>",
"       <td>",
"        Polyurethane workers, roofers, insulators, painters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anhydrides (eg, trimellitic anhydride, phthalic anhydride)",
"       </td>",
"       <td>",
"        Manufacturers of paint, plastics, epoxy resins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metals (eg, chromic acid, potassium dichromate, nickel sulfate, vanadium, platinum salts)",
"       </td>",
"       <td>",
"        Platers, welders, metal and chemical workers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drugs (eg, beta lactam agents, opiates, other)",
"       </td>",
"       <td>",
"        Pharmaceutical workers, farm workers, health professionals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wood dust (eg, Western red cedar, maple, oak, exotic woods)",
"       </td>",
"       <td>",
"        Carpenters, woodworkers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dyes and bleaches (eg, anthraquinone, carmine, henna extract, persulfate, reactive dyes)",
"       </td>",
"       <td>",
"        Fabric and fur dyers, hairdressers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amines",
"       </td>",
"       <td>",
"        Chemists, cleaners, plastic manufacturers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glues and resins (eg, acrylates, epoxy)",
"       </td>",
"       <td>",
"        Plastic manufacturers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Miscellaneous (eg, formaldehyde, glutaraldehyde, ethylene oxide, pyrethrin, polyvinyl chloride vapor)",
"       </td>",
"       <td>",
"        Laboratory workers, textile workers, paint sprayers, health professionals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        High molecular weight organic materials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Animal proteins (eg, domestic and laboratory animals, fish and seafood)",
"       </td>",
"       <td>",
"        Farmers, veterinarians, poultry processors, fish and seafood processors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flours and cereals",
"       </td>",
"       <td>",
"        Bakers, food processors, dock workers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enzymes (eg, pancreatic extracts, papain, trypsin, Bacillus subtilis, bromelain, pectinase, amylase, lipase)",
"       </td>",
"       <td>",
"        Bakers, food processors, pharmaceutical workers, plastic workers, detergent manufacturers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plant proteins (eg, wheat, grain dust, coffee beans, tobacco dust, cotton, tea, latex, psyllium, various flours)",
"       </td>",
"       <td>",
"        Bakers, farmers, food and plant processors, health professionals, textile workers",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28508=[""].join("\n");
var outline_f27_53_28508=null;
var title_f27_53_28509="Antibiotic regimens for tuboovarian abscess";
var content_f27_53_28509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotic regimens for tuboovarian abscess",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Regimens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose (adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_start\" colspan=\"2\">",
"        <strong>",
"         First choice",
"        </strong>",
"        *",
"        <sup>",
"         [1-4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefoxitin",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"       <td>",
"        2 g IV every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline",
"       </td>",
"       <td>",
"        100 mg orally or IV every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefotetan",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"       <td>",
"        2 g IV every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline",
"       </td>",
"       <td>",
"        100 mg orally or IV every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clindamycin",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"       <td>",
"        900 mg IV every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gentamicin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 mg/kg loading dose then 1.5 mg/kg every 8 hours IV or IM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ampicillin",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"       <td>",
"        2 g IV every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clindamycin",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"       <td>",
"        900 mg IV every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gentamicin (3-antibiotic regimen)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 mg/kg loading dose then 1.5 mg/kg every 8 hours IV or IM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ampicillin-sulbactam",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"       <td>",
"        3 g IV every 6 hours",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Doxycycline",
"       </td>",
"       <td>",
"        100 mg orally or IV every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Second choice",
"        </strong>",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Levofloxacin",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"       <td>",
"        500 mg IV once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metronidazole",
"       </td>",
"       <td>",
"        500 mg IV every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Imipenem-cilastatin",
"       </td>",
"       <td>",
"        500 mg IV every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Outpatient oral regimens",
"        </strong>",
"        (",
"        <strong>",
"         only",
"        </strong>",
"        as continuation of therapy in select patients)",
"        <sup>",
"         &loz;&sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Levofloxacin",
"        <strong>",
"         or",
"        </strong>",
"        Ofloxacin",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"       <td>",
"        500 mg orally once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metronidazole",
"       </td>",
"       <td>",
"        500 mg orally twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amoxicillin-clavulanate XR",
"       </td>",
"       <td>",
"        2000 mg extended release orally twice daily",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Antibiotic doses should be adjusted appropriately for patients with renal insufficiency or other dose-related consideration.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Alternatively gentamicin may be given 3 to 5 mg/kg IV once per day.",
"     <br/>",
"     &Delta; 3 g ampicillin-sulbactam is equivalent to 2 g ampicillin with 1 gram sulbactam.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     There are insufficient high quality data about this agent or regimen; coverage is theoretic.",
"     <br/>",
"     &sect; In select patients in whom clinical improvement has been clearly documented, continuation of therapy as an outpatient may be appropriate. Direct communication with the patient and a plan for follow-up must also be confirmed.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Workowski KA, Berman S. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"      </li>",
"      <li>",
"       Landers DV, Sweet RL. Tubo-ovarian abscess: contemporary approach to management. Rev Infect Dis 1983; 5:876.",
"      </li>",
"      <li>",
"       Reed SD, Landers DV, Sweet RL. Am J Obstet Gynecol 1991; 164:1556.",
"      </li>",
"      <li>",
"       Ginsburg DS, Stern JL, Hamod KA, et al. Am J Obstet Gynecol 1980; 138:1055.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28509=[""].join("\n");
var outline_f27_53_28509=null;
var title_f27_53_28510="OARS community questionnaire";
var content_f27_53_28510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    OARS multidimensional functional assessment questionnaire: Community version",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        Social resources",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        1. Are you single (never married), married, widowed, divorced, or separated?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td colspan=\"2\">",
"        Single (never married)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td colspan=\"2\">",
"        Married",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td colspan=\"2\">",
"        Widowed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td colspan=\"2\">",
"        Divorced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td colspan=\"2\">",
"        Separated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td colspan=\"2\">",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        2. Who lives with you?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &nbsp;&nbsp; 1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        No one",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp; 1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Husband or wife",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp; 1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp; 1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Grandchildren",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp; 1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Parents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp; 1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Grandparents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp; 1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Brothers and sisters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp; 1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Other relatives (does not include in-laws covered in the above categories)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp; 1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Friends",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp; 1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Non-related paid* helper",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp; 1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Other (specify):",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        3. How many people do you know well enough to visit with in their homes?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td colspan=\"2\">",
"        Five or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td colspan=\"2\">",
"        Three or four",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td colspan=\"2\">",
"        One or two",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td colspan=\"2\">",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        4. About how many times did you talk to someone - friends, relatives, or others - on the telephone in the past week (either you called them or they called you)? (If subject has no phone, question still applies.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td colspan=\"2\">",
"        Once a day or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td colspan=\"2\">",
"        Two to six times",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td colspan=\"2\">",
"        Once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        Not at all",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td colspan=\"2\">",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        5. How many times&nbsp;during the past week did you spend time with someone who does not live with you; that is, you went to see them or they came to visit you, or you went out to do things together?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td colspan=\"2\">",
"        Once a day or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td colspan=\"2\">",
"        Two to six times",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td colspan=\"2\">",
"        Once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        Not at all",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td colspan=\"2\">",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        6. Do you have someone you can trust and confide in?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td colspan=\"2\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td colspan=\"2\">",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        7. Do you find yourself feeling lonely quite often, sometimes, or almost never?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        Quite often",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td colspan=\"2\">",
"        Sometimes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td colspan=\"2\">",
"        Almost never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td colspan=\"2\">",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        8. Do you see your relatives and friends as often as you want to, or not?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td colspan=\"2\">",
"        As often as wants to",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        Not as often as wants to",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td colspan=\"2\">",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        9. Is there someone outside this place who would give you any help at all if you were sick or disabled, for example your husband/wife, a member of your family, or a friend?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td colspan=\"2\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        No one willing and able to help",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td colspan=\"2\">",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        (If \"Yes\" ask a.",
"        <strong>",
"         and",
"        </strong>",
"        b.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        <strong>",
"         a. Is there anyone who would take care of you as long as needed, or only for a short time, or only someone who would help you now and then (for example, taking you to the doctor, or fixing lunch occasionally, etc)?",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        3",
"       </td>",
"       <td colspan=\"2\">",
"        Someone who would take care of subject indefinitely (as long as needed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        2",
"       </td>",
"       <td colspan=\"2\">",
"        Someone who would take care of subject for a short time (a few weeks to six months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        1",
"       </td>",
"       <td colspan=\"2\">",
"        Someone who would help the subject now and then (taking him/her to the doctor or fixing lunch, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        -",
"       </td>",
"       <td colspan=\"2\">",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        <strong>",
"         b. Who is this person?",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" colspan=\"3\">",
"        Name:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" colspan=\"3\">",
"        Relationship:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" colspan=\"3\">",
"        <strong>",
"         Code:",
"        </strong>",
"        Spouse = 1, Sibling = 2, Offspring = 3, Grandchild = 4, Other kin = 5, Friend = 6, Other = 7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes free room.",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 1975, 1988 Duke University, Center for the Study of Aging and Human Development. All rights reserved. May not be used for financial gain. When reporting on information gathered through this measure please acknowledge the source: Older Americans Resources and Services MFAQ. Permission for use in major studies should be obtained from the Duke Aging Center (see site address below). Further information can be obtained from the website:",
"     <a href=\"file://www.geri.duke.edu\" target=\"_blank\">",
"      file://www.geri.duke.edu",
"     </a>",
"     . Click on Services, then click on Older Americans ..., and from the manual referenced there.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28510=[""].join("\n");
var outline_f27_53_28510=null;
var title_f27_53_28511="Blood glucose record PI";
var content_f27_53_28511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 627px\">",
"   <div class=\"ttl\">",
"    Blood glucose record",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 607px; height: 778px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_53_28511=[""].join("\n");
var outline_f27_53_28511=null;
